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RIASSUNTO 
 
In questa tesi di dottorato sono riportati la sintesi e lo studio della fototossicità e 
dell’interazione con il DNA di due nuove porfirine e dei corrispondenti renio(I) coniugati. 
Inoltre è riportato anche uno studio di targeting di cellule tumorali.  
La tesi è divisa in due sessioni. Nella prima è descritta la sintesi di due nuove porfirine 
solubili in acqua: una porfirina neutra e simmetrica e una porfirina carica e asimmetrica 
in cui, rispettivamente, uno o quattro chelanti [1,4,7]-triazaciclononano (TACN) sono 
legati al macrociclo attraverso uno o quattro linker idrofobici. Sono inoltre descritti 
anche i corrispondenti renio(I) coniugati. Il metallo renio(I) è stato inserito nella periferia 
del macrociclo sia per ottenere una molecola con un possibile effetto terapeutico che 
con una funzione diagnostica. Infatti, grazie alle simili proprietà del renio e del 99mTc 
radioattivo, i coniugati radioattivi del 99mTc(I) possono essere sintetizzati a partire dai 
corrispondenti Re(I) coniugati. I composti sintetizzati sono stati valutati come 
fotosensibilizzatori (PS) per la terapia fotodinamica (PDT). Gli studi in vitro di foto-
tossicità sono stati eseguiti sulle cellule HeLa (cellule del carcinoma della cervice 
uterina), H460M2 (cellule del carcinoma polmonare a non-piccole cellule) e HBL-100 
(cellule epiteliali non tumorali). Tre di questi composti non si sono dimostrati tossici al 
buio fino a 100 µM e, in seguito alla coordinazione del Re(I), è stato osservato un 
aumento della fototossicità solo per la porfirina carica e simmetrica. La localizzazione 
cellulare dei composti è stata studiata sulle cellule HeLa usando la microscopia a 
fluorescenza. Nonostante la loro scarsa localizzazione nucleare, i composti sono stati 
studiati per valutarne la capacità di legare il DNA, sia quadruplex che duplex, e il 
risultato di questi studi ha dimostrato una significativa selettività delle porfirine 
asimmetriche per il G-quadruplex. 
Nella seconda parte è descritto uno studio preliminare di targeting di una porfirina 
carica e asimmetrica sulle cellule tumorali. É noto infatti che l’accumulo delle porfirine 
nel tessuto tumorale è preferenziale ma non selettivo. L’aumento della selettività del 
fotosensibilizzatore può essere migliorata attraverso l’uso di peptidi. L’idea del progetto 
nasce dalla volontà di sintetizzare una molecola che possa essere un 
fotosensibilizzatore in PDT, che possa trasportare nel tessuto tumorale il Re(I) e che 
possa, grazie alla presenza del peptide, accumularsi in un specifico tessuto tumorale. 
Per questo è stata sintetizzata una molecola contenente una porfirina asimmetrica 
 solubile in acqua, il chelante TACN e la bombesina BN[7-14] come peptide, allo scopo 
di aumentare la sua selettività per il tumore alla prostata. La sintesi è stata svolta sia in 
soluzione sia in fase solida usando diversi approcci sintetici. Durante la sintesi 
multistadio, sono stati riscontrati alcuni problemi inerenti al legame con la porfirina. Per 
questo motivo solo una piccola quantità del composto finale è stata ottenuta e il 
corrispondente Re(I) coniugato non è stato sintetizzato. Infine, si è provato a sostituire 
la porfirina con un fullerene[60], essendo nota anche in questo caso la capacitá di agire 
come fotosensibilizzatore. Il corrispondente derivato contenente il fullerene, il peptide 
BN[7-14] e il chelante TACN è stato perciò sintetizzato. Così come nel caso 
precedente, la bassa resa e i problemi di purificazione non hanno consentito la sintesi 
del corrispondente Re(I) coniugato. 
I risultati di questa tesi di dottorato mostrano che una porfirina neutra e simmetrica e 
una porfirina carica e asimmetrica possono coordinare il frammento metallico fac-
{Re(CO)3}
+ in buone rese. Considerando i risultati biologici, c’è quindi la possibilità di 
ottenere il corrispondente 99mTc coniugato. Inoltre sono state sintetizzate una nuova 
porfirina e un nuovo fullerene entrambi leganti una peptide e un chelante. Per ovviare 
ai problemi riscontrati, sarà però necessario sviluppare una nuova strategia sintetica al 
fine di unire in una singola molecola una porfirina asimmetrica, un frammento di Re(I) 
ed il peptide BN[7-14] per il targeting del tumore alla prostata. 
ABSTRACT 
 
This PhD thesis reports the synthesis, the phototoxic activity, the DNA interactions of 
new porphyrins and their Re(I) conjugates and a first study to  the targeting of 
porphyrins to tumor cells. 
The thesis is divided in to two sections. In the first one the synthesis of two new water 
soluble porphyrins, a neutral fourfold-symmetric compound and a +3-charged tris-
methylpyridinium derivatives, in which either one or four [1,4,7]-triazacyclononane 
(TACN) units are connected to the porphyrin macrocycle through a hydrophilic linker, is 
described. The correspondent Re(I) conjugates are also reported. The Re(I) metal was 
inserted at the periphery of the macrocycle both to provide a possible additive 
therapeutic effect and to obtain a molecule with diagnostic feature. In fact, since the 
properties of the “cold” Re and of the “hot” 99mTc complexes are assumed to be very 
similar, the hot 99mTc(I) conjugate can be synthesized from the correspondent cold 
Re(I) conjugate. These compounds were evaluated as photosensitizers for 
photodynamic therapy (PDT). The in vitro (photo)toxic effects were evaluated towards 
the human cell lines HeLa (cervical cancer), H460M2 (non-small-cell lung carcinoma), 
and HBL-100 (non-tumorigenic epithelial cells). Three of the compounds were not 
cytotoxic in the dark up to 100 µM and upon Re(I) coordination an enhancement in the 
phototoxicity activity was observed only for the fourfold-symmetric compound. The 
intracellular localization of these compounds was studied on HeLa cells by confocal 
fluorescence microscopy. Although low nuclear localization was observed for some of 
them, it still prompted us to investigate their capacity to bind both quadruplex and 
duplex DNA and a significant selectivity in the tris-methylpyridinium derivates for G-
quadruplex was observed. In the second section a preliminary study on the targeting of 
photosensitizers towards cancer cells is described. Indeed, it is well known that the 
accumulation of porphyrins in the tumor tissues is only preferential and not selective. 
For this reason the use of targeting peptides is very promising in order to increase the 
tumor selectivity of the photosensitizer. The fundamental concept of the project was to 
synthesize a molecule that could be a good photosensitizer in PDT treatment, delivery 
into the tumor a Re(I) fragment and finally accumulate in a specific tumor. A molecule 
containing a water soluble +3-charged tris-methylpyridinium porphyrin, a [1,4,7]-
triazacyclononane (TACN) unit and the targeting peptide bombesin BN[7-14] was 
 synthesized in order to increase the selectivity on prostate cancer cells. The synthesis 
was performed both in solution and in solid phase using different approaches. 
Unfortunately, several synthetic problems were found concerning the reaction with the 
porphyrin unit. For this reason a really small amount of the final compound was 
obtained and the correspondent Re(I) conjugate was not synthesized. Since fullerene 
derivatives are good photosensitizers the correspondent molecule containing a 
fullerene unit, the BN[7-14] and the chelator TACN was synthesized,  but also in this 
case the yield was very low and the product was difficult to purify.  
The results of this PhD thesis show that a neutral fourfold-symmetric and a +3-charged 
tris-methylpyridiniumporphyrins can bind the fac-{Re(CO)3}
+ fragment in good yields. 
Considering the biological evaluations, the possibility of obtaining the correspondent 
99mTc conjugates, these results are interesting in order to develop new therapeutic 
agents. Furthermore, a new targeted porphyrin and fullerene containing a TACN unit, 
as a chelator for Re(I) metal fragments, were synthesized. A new synthetic strategy to 
obtain a single molecule able to target the charged tris-methylpyridinium porphyrin and 
a Re(I) fragment to prostate cancer cell is still to be discovered  in order to overcome 
low yield and hard purification procedures.  
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1.1. PHOTODYNAMIC THERAPY 
 
1.1.1. HISTORY OF THE DEVELOPMENT OF PHOTODYNAMIC THERAPY 
Cancer is one of the deadly diseases of our time and researchers from all over the 
world are actively involved in fighting it by developing new antitumor drugs. Several 
treatments are used such as surgery, radiation and chemotherapy. Unfortunately these 
treatments have important side effects: nausea, vomiting, in some cases depression of 
the immune system and loss of the normal organ functions. In addition, radiations give 
damage to the epithelial surfaces, infertility and swelling of soft tissues of the patients 
[1]. Nowadays photodynamic therapy (PDT) is used to treat several tumors such as 
skin, lung, gall bladder, esophagus, endo-bronchial, breast, stomach, oral cavity head 
and neck cancer and also skin’s premalignant lesions [2-4]. PDT is a minimally invasive 
treatment that destroys target cells in the presence of oxygen when the light irradiates 
a molecule generating highly reactive singlet oxygen (ROS). The origin of PDT goes 
back to the Egyptians as they first used sunlight to bleach fabrics. At the beginning of 
the nineties Finsen discovered that light treatment could control skin manifestations of 
tuberculosis. Later on Raab, Jesionek and Von Tappeiner discovered a relationship 
between the light activation of a dye and the therapeutic effect. Finally in the second 
half of the twentieth century Dougherty demonstrated that the topical administration of 
hematoporphyrin IX and red light eradicated mammary and bladder tumors in mice 
[5,6].  
 
1.1.2. MECHANISM OF ACTION OF PHOTODYNAMIC THERAPY 
The PDT treatment consists in several steps. First a non-toxic drug (named 
photosensitizer, PS) is administrated intravenously or topically to the patient. The so-
called time delay corresponds to the time that elapses between the PS’s administration 
and the illumination of the tumor tissue. During this incubation period the maximum 
drug uptake in the tumor is reached. The tumor is then irradiated usually with red light, 
thus the PS is converted from its low energy ground singlet state (S0) into a short-lived 
higher energy excited state (S1). The activated PS can transfer its energy or electrons 
to produce reactive oxygen species (ROS) or singlet oxygen (1O2). The activated PS 
causes apoptosis and/or necrosis, which appears in two or three days, with two types 
of mechanisms [7-10] (Figure 1). 
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                                               Figure 1: General mechanism of PDT [1] 
 
More in detail: i) the activated PS can react directly with a biological substrate (for 
example lipids, proteins and nucleic acids) to form free radicals which, after interaction 
with the molecular ground triplet state oxygen (3O2), can produce ROS (O2
-•, OH•, 
H2O2); ii) the activated PS can transfer its energy directly to oxygen converting 
3O2 to 
singlet oxygen 1O2. Singlet oxygen is a non-radical, highly reactive species, with a short 
lifetime in biological systems (< 0.04 µs). The damage caused by singlet oxygen is 
highly localized. For all these reasons  singlet oxygen is considered a potent cytotoxic 
agent [1, 11, 12] (Figure 2). 
 
Figure 2: Simplified Jablonski energy level diagram for PDT [11] 
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Besides the apoptosis and/or necrosis tumor death, the PS can cause cell death by 
damaging the blood vessels surrounding the tumor cells, thus preventing the cancer 
from receiving necessary nutrients and oxygen, and by activating the immune 
mediators against tumor cells [7,10,13].  
 
1.1.3. THE ROLE OF LIGHT IN PHOTODYNAMIC THERAPY  
Besides the presence of oxygen in the tumor tissue, also the light has an important role 
in PDT [14]. Upon interaction with a tissue surface, light can be reflected, scattered, 
transmitted or absorbed depending on the optical features of the tissue and on the light 
properties [15]. The features that the light source should have a total optical power 
(measured in Watts, W) at the appropriate wavelength to activate the PS and an 
optimal penetration in the tumor tissue [16]. In phototherapy light is used in the 
phototherapeutic window, the wavelength range between 600 and 900 nm [17]. 
Penetration of light into deeper tissues is only possible for wavelength >700 nm. For 
this reason the ideal PS would be activated at wavelength > 700 nm, but most of the 
PSs currently used are excited at lower wavelengths. The penetration in tissue of 
wavelengths < 600 nm is about 0.5 cm, while wavelengths >600 nm can double tissue 
penetration to 1 cm.  
The total light dose administrated during PDT depends on the type and size of the 
tumor and usually its fluence rate should not exceed 100 mW/cm2 to avoid thermal 
effects that can damage the cells.  
The choice of the type of light source depends on i) the location of the tumor; ii) the 
light dose delivered and iii) the choice of the PS. Lasers are the sources of light usually 
used in PDT treatment. An advantage of lasers is the ability to easily convey this light 
into fiber optics that allows the delivery of the activating photons directly to the target 
tissue [16]. With the laser the tumors located both internally and superficially can be 
irradiated. The standard source for clinical PDT is the argon/dye laser that can irradiate 
at 630 nm with a power from 1 to 7 W. In the past few years the research has also 
focused on the improvement of LEDs (light-emitting diodes) in order to use them in 
PDT. The advantages of this challenging instrument are: low price, versatility, less 
hazard, thermal nondestructive and readily availability. A very important feature of 
LEDs is the emission wavelengths that ranges from UVA to the near infrared (350 nm-
1100 nm) and the power that can reach up to 150 mW/cm2 over a 3 cm x 3 cm area 
[13, 18, 19]. 
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1.1.4. THE ROLE OF THE PHOTOSENSITIZER IN PHOTODYNAMIC THERAPY  
Several groups of molecules are used as PSs in PDT. To be considered a good PS a 
molecule should have the following characteristics: i) strongly absorb in the 600-800 
nm range; ii) produce singlet oxygen and cause the desired biological response; iii) be 
chemically pure; iv) have minimal dark toxicity and be cytotoxic only in the presence of 
light; v) be selectively uptaken by cancer cells prior to light activation; vi) be rapidly 
excreted from the body; vii) be easily administrated though various routes [6,13]. 
Basically three generations of PSs have been developed (Table 1). 
 
 
Table 1: Examples of photosensitizers [6] 
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The first generation includes porphyrins that were discovered in the 1970s and 1980s, 
for example Photofrin (Figure 4). The second generation of photosensitizers refers to 
the porphyrin derivates synthetized from the late 1980. The δ-aminolevulinic acid (ALA) 
belongs to this class and is already authorized in European Union for fluorescence-
guided resection. ALA is the biosynthetic precursor of heme since it can generate 
protoporphyrin IX (PpIX). Exogenous administration of 5-ALA can lead to an 
intracellular accumulation of PpIX (Figure 3) [1, 5, 10, 20-22]. 
 
 
Figure 3: Heme synthesis pathway [23] 
 
The third generation of photosensitizers includes drugs that are modified for example 
with antibodies in order to obtain a PS more tumor specific [5]. 
Also non-porphyrin (such as dyes) can be used as PSs. Rose bengal, eosin, methylene 
blue are good PSs as they can generate 1O2. Rose Bengal is frequently used as PS 
thanks to its high solubility in water, high singlet oxygen quantum yield and low rate of 
photobleaching (Figure 4) [12, 13, 24, 25]. 
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Figure 4: Structure of photosensitizers 
  
 
1.2. PORPHYRINS 
 
1.2.1. GENERAL INFORMATION ABOUT PORPHYRIN  
Porphyrins are often found in nature since they play several roles in a large number of 
biological processes such as photosynthesis and transport of oxygen in the blood. 
Indeed all the heme proteins (such as hemoglobin, cytochrome b and c and 
cytochrome P450) contain in their structure a molecule of porphyrin. Also other 
biomolecules as chlorophylls, phaeophytins and vitamin B12 have a porphyrin related 
structure [26].  
Porphyrins are a versatile class of π-conjugated macrocycles that have in their 
structure a cyclic tetrapyrrole in which the pyrrole rings are linked through their α 
carbon atoms by methine bridges (–CH=) (Figure 5).  
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Figure 5: Porphyrin structure 
 
The tetrapyrrole defines a cavity of dimension nearly perfect to coordinate a large 
number of metals usually Fe(III), Fe(II), Zn(II), Cu(II) and Co(II) giving rise to 
metalloporphyrins. Only diamagnetic metals (Zn, Pd, In, Sn, Lu) allow the tetradentate 
macrocycle to retain its photosensitizing ability, while paramagnetic (Fe, Cu, Gd) do not 
[27]. The macrocycle is highly conjugated, planar, rigid, aromatic, and chemically 
stable. Its low reactivity is the reason why reactions can be performed in the peripheral 
positions without modifying the central core. Another important feature for chemical 
applications is the stability of the porphyrin ring in strong acid and basic conditions. 
Porphyrins are amphoteric compounds having properties of both acids and bases in 
solution. The two nitrogen atoms that have an unpaired electron doublet (pKb ≈ 9) can 
be protonated by strong acids as TFA with formation of mono- and deprotonated 
species MP and DP (Figure 6). Furthermore strong bases, such as alkoxide, can 
remove the protons present on the nitrogen atoms (pKa ≈ 16) of the pyrroles giving a 
dianion [10]. 
 
 
 
Figure 6: Mono- and diprotonated species MP and DP. 
 
Many synthetic porphyrins bear phenyl rings in the meso positions. Besides their 
applications in biological field (in particular as antitumor agents for PDT, and 
antibacterial and antimicrobial agents) these compounds can be used in analytical 
chemistry, in organic solar cells as energy transfer systems, in oxidation catalysis, and 
in agriculture (as potential photoactivable herbicides, pesticides, insecticides) [28, 29]. 
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Furthermore, they could be also useful as tools for the detection of early-stage tumors 
exploiting their fluorescence properties. Porphyrins emit intense red fluorescence on 
irradiation with light of wavelength near 400 nm. Indeed as a consequence of the 
extensive electron delocalization, the electronic absorption spectrum of a typical 
porphyrin is very characteristic: it consists of the intense Soret band at ≈ 400 nm 
(strong transition to the second excited state, S0 -> S2) and four Q bands of lower 
intensity from 500 nm to 700 nm (weak transition to the first excited state, S0 -> S1) 
(Figure 7). 
 
 
Figure 7: UV-vis spectrum of a porphyrin. 
 
1.2.2. MECHANISM OF ACTION/DAMAGE AND SUBCELLULAR TARGETS  
It is well known that porphyrins selectively accumulate in the tumor tissue, but the 
mechanism is still not fully understood. Dolmans et al. postulate that porphyrin 
accumulation in tumors is due to the high vascular permeability of the agents, as well 
as their affinity for proliferating endothelium and the lack of lymphatic drainage in 
tumors. For this reason research is currently working to enhance selective tissue 
localization, using targeting strategies such as antibodies, peptides or nanoparticles 
[30]. 
Several factors are involved in the accumulation of porphyrins in the tumor tissue. In 
aqueous media porphyrin derivates show a strong tendency to form aggregated 
species and for this reason several porphyrins, once systemically injected into the 
bloodstream, become readily associated with hydrophobic regions of the specific 
plasma proteins, such as low-density lipoprotein (LDL) and high-density lipoprotein 
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(HDL) [31]. Besides the blood proteins transport several factors are involved in 
accumulation of porphyrins in the tumor tissues, such as: i) structure that determinates 
its molecular weight; ii) electronic charge; iii) hydrophobic nature; iv) affinity for 
biological ligands and v) type of formulation [32]. Moreover, other factors are 
determined by the characteristics of the tumor tissue [33-35]: i) the increased vascular 
permeability and the ineffective lymphatic clearance might cause the build-up of 
porphyrins in the interstitial spaces; ii) the decreased intratumoral pH may affect the 
ionization of derivative porphyrins; iii) the increase number of LDL receptors: it is 
known that porphyrins with a high level of lipophilicity have more affinity for LDL, 
instead the ones with a high level of hydrophilicity prefer either HDL or albumin. [36-
38]. Because of the high reactivity and short half-life of singlet oxygen and hydroxyl 
radicals, only molecules and structures that are proximal to the area of their production 
are directly involved in PDT and for this reason the damage depends on the subcellular 
localization of the PS. The PDT effects are different according to the cell type, 
consequently the degree of damage changes [20]. 
Focusing on the subcellular level, PDT interest membranes, cell surfaces, lysosomes, 
endoplasmic reticulum (ER), mitochondria and other cells organelles [39]. The ROS 
and the singlet oxygen molecules can produce oxidation and cycloadditions reactions. 
Indeed important targets are amino acids residues in proteins, such as cysteine, 
methionine, tyrosine, histidine and tryptophan [26, 40, 41]. Also unsaturated lipids such 
as cholesterol, undergo reactions to give lipid hydroperoxides [26] Since lipids and 
proteins are part of the biological membranes, the reaction between 1O2 and the 
components of the membrane causes alteration of the permeability of the membrane 
that leads to cytolysis, swelling, blistering on the cell membrane, release of vesicles 
containing enzymes, inhibition of enzymes of membranes such as Na+/K+-ATPase, 
destruction of the calcium channels [42-43]. In the mitochondria these events can lead 
to the release of cytochrome C and the rapid induction of apoptosis [44-46].  
Also DNA is a target of PDT, since it can be oxidative damaged at both the pyrimidine 
and purine bases (especially guanine) and at apurinic/apyrimidinic (abasis) sites such 
as the sugar moieties causing DNA damage, mutations and carcinogenesis to the 
tumor cells. As a result of PDT also single-strand (SSBs) and doublet-strand breaks 
(DSBs), and a directly inhibition of the DNA and RNA polymerase can be observed [26, 
47, 48]. Besides the effects of cell damages also the vascular damages are responsible 
of the tumor cell death. The vascular effects of PDT consist in inflammation processes, 
change of the vascular permeability and conformation, and finally vessel occlusion.. 
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Indeed PDT causes the invasion of leukocyte, lymphocytes, neutrophils, macrophages, 
cytokines, interleukin IL-6 and IL-1 [49] and this was observe during PDT with  
Photofrin on mouse EMT6 tumors. PDT changes the endothelium of the vases and this 
leads to the change of the permeability and structure of blood vessels. In fact after 
irradiation there is a cascade of biological responses such as the accumulation of 
macrophages and plates, release of cytokines and prostaglandins, and the plates 
aggregation causes thrombus formation [7, 20, 50]. 
 
 
 
2. 
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2.1. PORPHYRINS AND RADIOPHARMACEUTICALS 
  
In recent times research has focused on the preparation of multifunctional agents that 
might combine in a single molecule both imagining and treatment properties. For this 
purpose we took in consideration rhenium compounds. So far relatively few rhenium 
complexes have been explored as potential anticancer agents, although they possess 
excellent properties for developing a novel class of antineoplastic drugs [51-54]. 
Notably, certain organometallic rhenium complexes have been found to have 
interesting luminescence properties which allow their intracellular distribution as well as 
their mechanism of action to be followed by emission microscopy [55]. In Figure 8 two 
rhenium complexes are shown and their IC50 values are compared to the one of 
cisplatin [56]. 
 
 
 
 
Figure 8: a) IC50 (µM) on MDA-MB- 468 cell line: Re compound 4.0 ± 6.5                 
and cisplatin 5.0 ± 2.5   b) IC50 (µM) on HeLa cell line: Re compound 7.7 ± 
1.0, cisplatin 25.6 ± 2.3 
The most attractive property of rhenium is that its chemistry is similar to that of the hot 
technetium, and for this reason it is frequently used as nonradioactive surrogate for the 
characterization of 99mTc complexes [57]. 99mTc radiopharmaceuticals play an important 
role in widespread applications of nuclear medicine. 99mTc complexes themselves 
represent the first generation of radiopharmaceuticals, and several chelators have 
been studied for the coordination of this radioactive element. For example 99mTc-DTPA 
and 99mTc-EHIDA derivate are used in radiodiagnostic respectively for the kidney and 
liver scintigraphy (Figure 9) [58].  
 
 
 
 
 
 
 
Figure 9: DTPA and EHIDA chelators for 
99m
Tc 
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In the second generation of radiopharmaceuticals the radionuclide is delivered in the 
tumor tissue by a targeting molecule. Two approaches have been studied for this 
purpose: i) an integrated design where the 99mTc unit is incorporated into the bioactive 
molecule; ii) a bifunctional approach, which couples a receptor-binding organic 
molecule to a metal chelate via a spacer [58, 59]. These latter molecules are made of a 
targeting molecule and a bifunctional chelator (BFC) (Figure 10). Indeed the chelator 
must be able both to coordinate the radioactive element and to connect it to the 
targeting molecule. The spacer is important since it both influences the lipo- or 
hydrophilicity of the radiopharmaceutical and separates the bioactive part from the 
metal-complex, thus minimizing steric effects [60-62].  
Many biomolecules, including monoclonal antibodies and small peptides, have been 
studied as “carriers” for radionuclides and several molecules are under development, 
for example Neotec1 (99mTc-Arcitumomab), where the carrier is a monoclonal antibody, 
to target colorectal cancer cells [63]. An alternative approach has been proposed by 
our research group. We selected a water soluble porphyrin to act as targeting 
molecule: besides being highly fluorescent, it might behave as carrier ligand for the 
active transport of metal compounds, including radiotracers, into cancer cells (Figure 
10). In fact this macrocycle typically shows preferential uptake by tumor tissues, as 
already discussed.  
 
 
Figure 10: Structure of second generation radiopharmaceuticals using BFC 
 
 
99mTc/Re-porphyrins are very interesting since, by applying the matched pair paradigm, 
the 99mTc/Re-porphyrin conjugates may act as multifunctional agents endowed either 
with diagnostic (99mTc) or with therapeutic properties (Re) [64]. In principle, 
radioimagining performed on a labeled 99mTc(I)-porphyrin might allow noninvasive, in 
vivo localization of the corresponding PDT active cold Re conjugate. There are 
however relatively few examples of water-soluble 99mTc/Re-porphyrin adducts. More 
recently, we described the preparation and characterization of two novel water-soluble 
porphyrins bearing three meso-pyridyl rings and one peripheral chelator, which was 
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either a diethylenetriamine unit (Figure 11, a) or a bipyridyl fragment (Figure 11, c). 
Both chelators were suitable for complexation of the {99mTc/Re(CO)3}
+ moieties (Figure 
11, b and d) [65, 66].  
 
 
Figure 11: Structure of monofunctionalized Re/
99m
Tc-porphyrin conjugates 
 
 
2.2. DNA INTERACTIONS OF PORPHYRINS 
 
The ability of cationic porphyrins and their metal complexes to interact with nucleic 
acids is well documented [67-71], and one of the most extensively investigated 
compound is meso-tetrakis-(4-N-methylpyridiniumyl)porphyrin (TMPyP) (Figure 5). The 
original studies of Fiel and coworkers on the interactions of TMPyP with DNA was 
aimed at developing DNA-targeting photosensitizers, since selective photocleavage of 
DNA in tumor cells might result in lethal damage to the cells [68, 72, 73]. Furthermore, 
cationic porphyrins were recently exploited for selective recognition of non-canonical 
DNA structures called G-quadruplexes [74-78]. The formation of G-quadruplex DNA 
structures in vivo has been associated with a number of key biological processes such 
as regulation of gene expression and telomere maintenance. In general, cationic 
porphyrins with relatively long and flexible side-arms are better binders of G-quartets 
compared to TMPyP, presumably because they might permit the stacking of the 
aromatic porphyrin core on the G-tetrad minimizing steric clashes with the G-tetrad 
edges. In Figure 12 the structure of a Mn-porphyrin synthetized by Meunier and 
coworkers is shown. This porphyrin with four cationic and flexible peripheral 
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substituents is 10000 times more selective for G-quadruplex DNA respect to duplex 
DNA [76]. 
 
 
Figure 12: TMPyP and the Meunier’s cationic Mn-porphyrin 
 
Consequently, there is a mounting interest in synthetizing cationic porphyrins as G-
quadruplex ligands, in particular to obtain molecules endowed with an increased affinity 
for the telomeric structures by virtue of additional interactions [29]. Due to the important 
biological roles associated to G-quadruplexes, they are potential targets for anticancer 
drug candidates [79-83]. Moreover, as was already described in the introduction, DNA 
can be damaged by exogenous and endogenous oxidative stress induced by reactive 
oxygen (ROS). 
 
 
2.3. STRATEGIES FOR THE DEVELOPMENT OF NEW RHENIUM 
PORPHYRINS 
 
For all the reasons detailed above, we decided to investigate tetrapyrrolic 
chromophores suitable for the conjugation with Re fragments to be potentially used 
both in therapy and diagnosis of cancer. Here we describe the synthesis, 
characterization, cellular localization, affinity evaluation for both quadruplex and duplex 
DNA, and the (photo)-toxic behavior of two novel porphyrins functionalized with either 
four or one [1,4,7]-triazacyclononane (TACN) peripheral units, the neutral 9 and the 3+ 
charged 16, as well as of their corresponding tetracationic Re(I)-conjugates 20 and 21. 
The bifunctional chelator is connect to the macrocycle through an hydrophilic 2,2'-
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(ethylenedioxy)diethylamine linker (Figure 13 and 14) that, besides increasing the 
water solubility of the final molecule, also increase its flexibility.  
 
 
Figure 13: Structure of porphyrins 9 and 20 
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Figure 14: Structure of porphyrins 16 and 21 
 
Porphyrins 9 and 16 were specifically designed for binding a facial metal fragment such 
as Re/99mTc(CO)3. In fact, the neutral TACN chelating unit matches the binding 
preferences of those metal fragments providing a relatively rigid set of three 
thermodynamically and kinetically stable bonds. Porphyrins 9 and 16 are an evolution 
of monofunctionalized porphyrins a and c shown in Figure 11 [65, 66]. Of note, the 
open-chain diethylenetriamine ligand has a worse geometrical match than TACN and, 
being flexible, is a less efficient binder than TACN. The bidentate bipyridyl ligand is 
hydrophobic in nature and leaves an hydrolysable position upon coordination with 
Re/Tc(CO)3 fragment (Figure 11, d). The coordination chemistry of Re(I)/Tc(I) with 
TACN as a ligand is well documented, and a variety of complexes containing rhenium, 
as well as technetium, in the formal oxidation state (I) with TACN have been already 
reported [82-87].  
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2.4. SYNTHESIS AND CHARACTERIZATION OF NEW PORPHYRINS 
 
In order to synthesize porphyrins 9 and 16, a suitably functionalized TACN derivate, 2-
(diBoc)TACN acetic acid (4), was synthesized in good yield by selective 1,4-bis-
protection of the amino groups of the commercially available TACN (1) [88], followed by 
reaction with benzyl bromoacetate, affording 3 in good yield. After reductive 
deprotection with H2 on Pd/C the functionalized chelator 4 was obtained (Scheme 1).  
 
 
Scheme 1: Synthetic route for 4. Reagents and conditions: a) TEA, CHCl3, (Boc)2O, CHCl3, Ar, 12 h, rt, 56%; b) benzyl 
bromoacetate, TEA, CHCl3, 0°C,1h, rt, 48 h, 89%; c) H2, Pd/C, CH3OH, 24 h, 91% 
 
Concerning porphyrin 9 synthesis, the condensation of pyrrole and methyl 4-formyl 
benzoate [89] followed by hydrolysis in basic conditions in THF/MeOH, gave the meso-
4'-tetracarboxyphenylporphyrin (TCPP) 5. 
The four carboxylic groups of 5 were activated with HOBt and coupled with the free 
amino group of the spacer N-Boc-2,2'-(ethylenedioxy)diethylamine 6. After column 
chromatography porphyrin 7 was obtained in high yield and purity (Scheme 2).  
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Scheme 2: Synthetic route for 5 and 7. Reagents and conditions: a) propionic acid, reflux, 1,5 h, 21%; b) KOH aq 
40%, THF/CH3OH 2:1, 40°C, 30 min, 91.5 %; c) DMAP, EDCI, HOBt, DMF, 24 h rt, 74% 
 
The Boc amino groups of 7 were then quantitatively deprotected using TFA in CH2Cl2 
obtaining the intermediate as TFA salt that was used for the following step without 
purification. The coupling reaction between the hydroxybenzotriazole (HOBt) ester of 
4 and the terminal amino groups of the porphyrin intermediate in anhydrous DMF 
gave after purification by column chromatography, the Boc-protected porphyrin 8 as a 
purple solid in high yield. The intermediate was quantitatively deprotected using TFA 
in CH2Cl2 and neutralized with TEA to give the neutral fourfold-symmetric porphyrin 9 
(Scheme 3). As this compound is very hygroscopic it appears as a sticky purple semi-
solid. 
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Scheme 3:  Synthetic route for 8 and 9. Reagents and conditions: a) TFA, CH2Cl2, 2 h, rt;  b) DMAP, EDCI, HOBt, DMF, 
overnight, rt, 66%;   c) TFA, CH2Cl2, 4 h, rt; d) CH3OH, TEA, Et2O, 97%.   
 
The 1H NMR spectrum of 9 in CD3OD (Figure 15) shows in the downfield region a 
broad singlet at δ 8.88 of the 8 Hβ and at δ 8.34 two doublets of the 16 H of the phenyl 
rings. The spacer and TACN protons resonate in the upfield region of the spectrum as 
eight multiplets and the chemical shifts were assigned by means of the conventional 
2D correlation spectra and by comparison with the intermediates previously 
synthesized and characterized. More in detail, the protons of the four CH2O groups of 
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the spacer resonate as four multiplets between δ 3.83 and 3.64 and are bound to 
carbon atoms that resonate at δ 70 (Figure 16). The multiplet at δ 3.78 accounts both 
for the protons of one CH2O and one CH2NH of the spacer (cross peak respectively at 
δ 70 and 40 in the HSQC spectrum). The multiplet at δ 3.47 shows two correlation 
peaks in the HSQC spectrum, suggesting the superimposition of two resonaces: the 
multiplet of the CH2NH protons of the spacer (cross peak at δ 39) and the singlet of Hd 
protons (cross peak at δ 57). The TACN protons resonate as three multiplets at δ 3.22, 
3.04 and 2.86. The most upfield multiplet is attributed to the protons in a position and it 
correlates with a carbon atom at δ 50 in the HSQC spectrum. Since the H-H COSY 
spectrum shows the correlation between this resonance and the multiplet at δ 3.04, this 
signal was assigned to protons in b position, while the multiplet at δ 3.22 account for 
the protons in c position. It is noteworthy that the protons in b and c position correlate 
with carbon atoms (δ 44 and 45 respectively), bound to the same chemical function, a 
secondary amino group. 
 
 
Figure 15: 
1
H NMR (CD3OD) of 9 
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Figure 16: HSQC (CD3OD) of 9  
Porphyrin 4'-TrPyMMeP (10) was synthesized starting from the condensation of 4-
pyridylcarboxyaldehyde, methyl 4-formyl benzoate and pyrrole in a 3:1:4 molar ratio 
under Alder-Longo conditions, followed by accurate chromatographic separations of 
the statistic mixture of the isomeric porphyrins (Scheme 4) [89].  
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Scheme 4: Synthetic route for 4'-TrPyMMeP. Reagents and conditions: propionic acid, reflux, 2 h, CH3OH/ C2H6O2, 
6.5% (absolute yield for 10) , 45.5% (relative yield for 10) 
 
Hydrolysis of the ester of 10 in THF/CH3OH under basic conditions gave porphyrin 11 
(Scheme 5). The hydroxybenzotriazole (HOBt) ester of 11 was then coupled with the 
terminal amino group of 6 in anhydrous DMF and, after purification by column 
chromatography, the Boc-protected intermediate 12 was obtained as a purple solid in 
high yield. Methylation of this intermediate with excess of methyl iodide in anhydrous 
DMF gave the tricationic porphyrin 13 as iodide salt in almost quantitative yield. The 
intermediate 13 was deprotected in acidic conditions obtaining 14 as TFA salt (Scheme 
5). 
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Scheme 5: Synthetic route for 11-14. Reagents and conditions: a) KOH aq 40%, THF/CH3OH 2:1, 40°C, 5 h, 100 %; b) 
DMAP, EDCI, HOBt, DMF, 20 h rt, 81%; c) CH3I, DMF, 90°C, 3 h, 87%; d) TFA, CH2Cl2, 3 h, rt, 97% 
 
From the HSQC spectrum in CD3OD of 14 it was established that the CH2 bound to the 
free amino group resonates as a multiplet at δ 3.18 (Figure 17). 
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Figure 17:  HSQC spectrum (CD3OD) of 14, upfield region. 
 
The carboxylic group of 4 was then coupled with the amino group of 14 in anhydrous 
DMF using HOBt, EDCI and DMAP. The coupling reaction was performed in a 
microwave oven at 60 °C. This technique was used for it excellent results, since 
microwave-enhanced chemistry is based on the efficient heating of materials by 
microwave dielectric heating effects: specific material (solvent or reagent) are able to 
absorb microwave energy and convert it into heat. Microwave irradiation produces 
efficient internal heating by direct coupling of microwave energy with the molecules that 
are present in the reaction mixture [90]. In the coupling reaction to synthesize 15, the 
microwave irradiation reduced the reaction time from 24 hours to 6 minutes and 
increased the yield from 54% to 66%. A higher reaction time and temperature were not 
used to avoid degradation phenomenon that was observed from the TLC analysis. 
Compound 15 was purified by several precipitations and washes with Et2O and CH2Cl2. 
This intermediate was quantitatively deprotected using TFA and treated with TEA to 
give the +3-charged monofunctionalized porphyrin 16 (Scheme 6).  
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Scheme 6: Synthetic route for 15 and 16. Reagents and conditions: a) DMAP, EDCI, HOBt, DMF, MW 6 min, 60 °C MW 
66%; b) TFA, CH3OH, 3 h, rt; c) CH3OH, TEA, Et2O, 98% 
The 1H NMR spectrum of porphyrin 16 in CD3CN (Figure 18) shows in the downfield 
region two doublets for the pyridyl protons at δ 9.13 (2,6 py) and 8.83 (3,5 py). These 
protons are bound to carbon atoms that resonate respectively at δ 144 and 133 in the 
heterocorrelated spectrum (Figure 19). Two multiplets at δ 9.06 and 8.98 are observed 
for the 8 Hβ and at δ 8.30 the 4 H of the phenyl ring resonate as a multiplet. The 
resonances of the methyl groups of the pyridyl rings are observed as two singlets at δ 
4.69 and 4.70 (cross peak at C48 in the HSQC spectrum, Figure 20). In the upfield 
region the protons of the spacer and of the chelator resonate between δ 3.79 and 2.82. 
The multiplets at δ 3.79, 3.72, 3.66 and 3.58 are attributed to the CH2O groups (cross 
peaks at C70 in HSQC spectrum). The multiplet at 3.72 accounts also for the 2 H of 
CH2NH (cross peak at C39 in HSQC spectrum). The multiplet at δ 3.38 accounts for 
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the 2H of the CH2 d and for the 2H of the CH2NH (cross peak respectively at C57 and 
C39 in HSQC spectrum). The TACN protons resonate at δ 3.29, 3.02, 2.82 (cross peak 
respectively at C43, C44, C49 in HSQC spectrum). The H-H COSY spectrum confirms 
these correlations (Figure 21). 
 
 
 
 
Figure 18:  
1
H NMR spectrum (CD3CN) of 16 
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Figure 19:  HSQC spectrum (CD3CN) of 16, downfield region 
 
 
Figure 20:  HSQC spectrum (CD3CN) of 16, upfield region  
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Figure 21:  H-H COSY spectrum (CD3CN) of 16 
 
Also tris-pyridinium porphyrin 19 was synthesized (Scheme 7). For this purpose the 
intermediate 12 was deprotected in TFA and neutralized with TEA to give porphyrin 17. 
The upfield region of the 1H NMR spectrum of 17 in CD3OD was superimposable on 
the one of the +3-charged tris-methylpyridinium derivate 14. In Figure 22 the ESI-MS of 
17 is reported. 
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 Scheme 7: Synthetic route for 17-19. Reagents and conditions: a) TFA, CH2Cl2, 3 h, rt; b) CH3OH, TEA, Et2O, 100%;   
c) DMAP, EDCI, HOBt, DMF, MW  6 min 60°C, 70.5%; d) TFA, CH2Cl2, 3 h, rt; e) CH3OH,   TEA, Et2O, 100% 
 
 
Figure 22:  ESI-MS spectrum of 17 
792.4 
[M+H]
+
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The amino group of 17 was coupled with the carboxylic group of 4 (Scheme 8). The 
reaction occurred only using microwave heating and EDCI and HOBt as coupling 
reagents. The purification by column chromatography gave the Boc-protected 
intermediate 18. After deprotection and neutralization the neutral tris-piridinium 
porphyrin 19 was obtained as a dark brown solid. This porphyrin is soluble in H2O, 
DMSO, CH3CN as the +3-charged tris-methylpirydinum porphyrin 16 but also in CH3OH 
and CH2Cl2.  In Figure 23 the HSQC spectrum in CD3OD of 19 is reported. 
 
 
 
 
 
 
Figure 23: HSQC spectrum (CD3OD) of 19 
 
The fourfold symmetric porphyrin 9, the +3 charged tris-methylpyridinium porphyrin 16 
and the neutral tris-pyridinium porphyrin 19 are very soluble in water and this makes 
them suitable for the labeling with 99mTc. For this reason it is interesting to synthesize 
their correspondent rhenium conjugates. We obtained the rhenium conjugates of 
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porphyrins 9 and 16 but surprisingly we were not able to synthetize the conjugate of the 
neutral tris-pyridinium porphyrin 19.  
To obtain the rhenium conjugates 20 and 21, each porphyrin was reacted with the Re(I) 
precursor [Re(CO)3(dmso)3](OTf) (Scheme 8). The rhenium conjugate of the neutral 
fourfold-symmetric porphyrin 20 was obtained at reflux in anhydrous CH3OH in argon 
atmosphere, while the rhenium conjugate of the +3-charged tris-methylpyridinium 
porphyrin 21 required a microwave reaction. In order to find the experimental 
microwave conditions, a model coordination reaction of rhenium to the chelator TACN 
(1) was performed in a microwave reactor. After heating for 10 minutes at 110 °C the 
coordination reaction was complete and compound 22 was afforded in quantitative 
yield. The 1H NMR spectrum in D2O of 22 is reported in Figure 24.  
 
 
 
Figure 24: 
1
H NMR spectra (D2O) of 22 
 
Conjugates 20 and 21 were obtained in high yield and purity and both reactions were 
monitored by TLC and by recording 1H NMR spectra of the reaction mixtures at time 
intervals (Figure 25 and 26). 
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Scheme 8: Synthetic route for 20 and 21. Reagents and conditions: a) anhydrous CH3OH, 48 h, reflux, 65%;                 
b) anhydrous CH3OH, MW 10 min, 110 °C, 73% 
 
As a result of the coordination reaction, the resonances of Hd and NH of TACN moved 
significantly downfield in the 1H NMR spectra of 20 and 21. These resonances are 
diagnostic of the product formation and their integration increases over time, as it can 
be observed for 20 in Figure 25.  
 
 
 
 
New Porphyrins and Re(I)-Conjugates 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: 
1
H NMR spectra (CD3OD) monitoring the formation of 20 after 6, 13 and 30 h 
 
In the synthesis of Re-conjugate 21 the proton spectrum recorded after 20 minutes of 
MW irradiation time showed, besides the Hd singlet, several resonances between δ 
4.0-4.3, and this could be due to the degradation of the product (Figure 26). For this 
reason the reaction was stopped after 10 minutes of irradiation at 110 °C as found in 
the model reaction.   
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Figure 26. 
1
H NMR spectra monitoring the formation of 21 in CD3CN, after 10, 20, 30, 40 min of reaction time in a 
microwave reactor. Degradation is visible after 20 min of reaction 
 
The rhenium conjugates 20 and 21 show similar mono- and bidimensional spectra.  
After the Re(I) coordination, the NH of TACN resonate at δ 6.83 and 5.90 respectively 
for 20 and 21 in the proton spectra . Surprisingly the position of the CH2 protons of 
TACN is not substantially influenced upon Re(I) coordination and they resonate as a 
series of multiplets between δ 3.3 and 2.6. Instead, the resonance of Hd is the most 
affected since it moved downfield of ≈ 0.7 ppm for both the conjugates (Figure 27, 28). 
t = 40 min 
t = 30 min 
t = 20 min 
t = 10 min 
t = 0 
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Figure 27: 
1
H NMR spectrum (CD3OD) of 20 
 
 
 
Figure 28: 
1
H NMR spectrum (CD3CN) of 21 
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Another important feature is that the CH2 groups of TACN are not anymore equivalent 
after the metal coordination, and for this reason in the HSQC spectra of both 20 and 21 
two cross peaks are found for each methylene group at the same chemical shift of the 
carbon atom (C56 for Ha, C51 and C49 for Hb and Hc) (Figure 29 and 30).  
 
 
Figure 29: HSQC spectrum (CD3OD) of 20 
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Figure 30: HSQC spectrum (CD3CN) of 21 
 
For both conjugate 20 and 21 the Hb and Hc protons of TACN showed strong 
correlation in the H-H COSY spectrum with NH of TACN (Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: H-H COSY spectrum (CD3CN) of 21. 
CH2NH 
CH2O 
CH2 d 
CH2 b/c 
CH2 c/b 
CH2 a 
CH3 OH 
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To confirm the coordination of Re(CO)3 unit, an IR spectrum was recorded for both 
conjugates. The spectrum shows two bands for the stretching of the CO groups of the 
metal fragment for porphyrin 20 (at 1912 and 2027 cm-1) and 21 (at 1977 and 2104 cm-
1). The 19F NMR in CD3CN of 21 (Figure 32) showed two resonances at δ -79.3 for the 
fluorine atoms of the triflate (CF3SO3
-) and at δ -75.4 for the ones of the trifluoroacetic 
(CF3COO
-) in a 1:3 ratio. From this data we estimated that 21 contain three triflate and 
one trifluoroacetic as counter ions.   
 
 
 
 
Figure 32: 
19
F NMR spectrum (CD3CN) of 21  
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2.5. BIOLOGICAL EVALUATIONS OF NEW RHENIUM PORPHYRINS 
 
We decided to evaluate porphyrin 9, 16 and the Re(I) porphyrins 20 and 21 as potential 
PSs [39]. For this reason several experiments were performed in particular to assay 
their (photo)toxicity and their DNA interactions. 
 
 2.5.1. (PHOTO) TOXICITY STUDIES 
This work was performed in collaboration with Professor Alberta Bergamo - Callerio 
Foundation Onlus, Trieste 
The in vitro (photo)toxic effects of the compounds towards the human cell lines HeLa 
(cervical cancer), H460M2 (non small-cell lung carcinoma), and HBL-100 (non 
tumorigenic epithelial cells) were evaluated. The photoxicity of compounds 9 and 20 
was found to increase upon to the total light dose used: by irradiating tumor cells at 
increasing total light doses from 1 to 10 Jcm-2, the dose-response curve shifts to the 
left, and the IC50 values correspondingly decrease (Figure 33). 
 
 
Figure 33: Light dose–effect curves for 9 and 20 as representative porphyrins. HeLa and H460M2 cells were exposed to 
doses from 0.1 to 100 mm for 24 h, then the cells were irradiated at λ=650 nm with a fluence rate of 14 mW cm
-2
 and 
total light doses ranging from 1 to 10 J cm
-2
. Cell cytotoxicity was determined 24 h after the end of irradiation by MTT 
test. 
 
9 
 
 
19 
 
 
9 
 
 
19 
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As it can be observed from Table 2, all compounds were found to be non-cytotoxic in 
the dark, with the exception of 20, which proved to be cytotoxic towards both H460M2 
and HBL-100 cell lines, with IC50 values of 7.4 and 33.7 µM, respectively, but not 
towards HeLa cells at the maximum concentration used in our experimental settings. 
This result is consistent with the observations previously reported [55-57] that 
tetrasubstituted Ru(II)-porphyrin conjugates typically show remarkable cytotoxicity in 
the absence of light. The negligible dark cytotoxicity of 21 is consistent with the one 
found for monosubstitute Ru(II)-porphyrins- conjugate by several research groups [91-
94].  
After exposure to red light, the monofunctionalized compounds 16 and 21 were 
consistently less active than the tetrafunctionalized compounds 9 and 20 under the 
same experimental conditions. In particular 16 and 21 are not effective at the lowest 
light dose (1 J cm-2) on all the cell lines (IC50 values >100 µM). Instead, an activity from 
mild to moderate was always observed at 10 J cm-2, with a greater effectiveness of 
both porphyrins against the H460M2 tumor cell line (IC50: 13 and 12 µM for 16 and 21, 
respectively). A comparison between compound 9 and 20 reveals a greater phototoxic 
effect of the latter against the HeLa cell line at all light dose (e.g., PI at 10 J cm-2 >7.8 
and >71.4, respectively). Conjugate 20 showed a PI value >38.5 upon irradiations at 5 
J cm-2, which is consistent with the PI of known PSs as photofrin and hypericin [95] 
(>10 and >43, respectively, at the same light dose) [96]. On the other hand 9 is 77-fold 
more active after irradiation at 10 J cm-2 on H460M2 cells, whereas 20 has much lower 
PI (>14.8 both at 5 and 10 J cm-2). The cytotoxicity activity of 20 on H460M2 cells in the 
dark, with an IC50 value very close to that found after photo-irradiation indicates a 
different sensibility between the two cell lines. These results suggest that 20 is not 
suitable for non-small-cell lung cancers, but it could be used in PDT for other tumor 
types that similarly show a different sensitivity between dark and irradiated conditions. 
In compound 21 the rhenium fragment does not enhance the phototoxicity compared to 
16, suggesting that other features (hydrophilicity, permanent positive charges, one 
flexible arm etc.) might play a major role in determining their phototoxic properties. 
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Table 2: Cells were exposed for 24 h to each compound at concentrations 0.1, 1, 3, 10, 30 and 100 μM. Subsequently, 
cells were irradiated with red light (650 nm) with a fluence rate of 14 mW/cm
2
 for increasing time intervals corresponding 
to total light doses of 1Jcm
-2
, 5 Jcm
-2
 or 10 Jcm
-2
. These light doses do not affect proliferation of untreated cells in 
control experiments. Cell cytotoxicity was determined using the MTT assay 24 h post-irradiation. Cells treated with the 
same concentrations of the test compounds, but kept in the dark, were used as controls. Statistics: ANOVA Analysis of 
variance and Tukey-Kramer post test. Statistical analysis is not reported in the table. 
b: PI = IC50 in the dark/IC50 upon irradiation. 
c: ND = not determinable 
 
2.5.2. DETERMINATION OF SINGLET OXYGEN QUANTUM YIELDS (ΦΔ) 
 
As it was already described, the main mechanism of action in PDT involves the 
generation of 1O2 after photoexcitation of the PS. For this reason 
1O2 quantum yield 
(ΦΔ) of the compounds was evaluated in DMSO. Tipically a clinically useful PS has ΦΔ 
value of ~0.5 [97]. Among the investigated porphyrins, the best singlet oxygen 
generator was 9 (ΦΔ = 0.63) while compounds 16, 20 and 21 had lower values (ΦΔ= 
0.31, 0.20, 0.19 for 20, 16 and 21 respectively). However, despite being the best 1O2 
generator, 9 showed lower potency than 20 in the phototoxicity assay, probably due to 
its low cellular uptake. Instead the low ΦΔ value of 16 and 21 might be related to their 
low activity on all cell lines after light irradiation. Since the ΦΔ values were determined 
in DMSO that is a different environment of the in vivo conditions, the phototoxic 
potencies of the compound are not predictable only on the basis of their ΦΔ values. 
 
 
  Dark 1 J/cm
2
 PI
b
 5 J/cm
2
 PI
b
 10 
J/cm
2
 
PI
b
 
HeLa 9 >100 >100 ND
c
 >100 ND
c
 12.9± 3.0 >7.8 
 20 >100 32.6±4.4 
4.44.4 
>3 2.6 ± 1.6 >38.5 1.4± 1.3 >71.4 
 16 >100 >100 ND
c
 >100 ND
c
 100 41 >1 
 21 >100 >100 ND
c
 100 ND
c
 73  19 >1.4 
         
H460M2 9 >100 35.5± 7.7 >2.8 4.3 ± 1.3 >23.3 1.3± 0.6 >77 
 20 7.4 ± 2.0 2.8 ± 1.4 >2.6 0.5 ± 0.2 >14.8 0.5± 0.2 >14.8 
 16 >100 >100 ND
c
 100 ND
c
     13  1 >7.7 
 21 >100 >100 ND
c
 58  9 >1.7 12  5 >8.3 
         
HBL-100 9 >100 82.0 7.4 >1.2 4.8  2.9 >20.8    1.4 0.9 >71.4 
 20  33.714.55 9.4  3.4 >3.6 1.0  0.3 >33.7   0.5 0.1 >67.4 
 16 >100 >100 ND
c
 76.6 1.6 >1.3   23.42.0 >4.3 
 21 >100 >100 ND
c
 75.4 0.1 >1.3   42.8 5.3 >2.3 
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2.5.3. CELLULAR LOCALIZATION STUDIES 
 
This work was performed in collaboration with Dr. Vanessa Pierroz and Professor 
Gilles Gasser - Department of Chemistry, University of Zurich  
 
The intracellular localization in HeLa cells of the compounds was determined using 
confocal fluorescence microscopy. After incubation for 2 h at 20 µM only compound 20 
displayed a significant cellular internalization. These data are in agreement with the 
antiproliferative experiments. However, upon light irradiation compound 9 and 21 
showed toxicity, indicative of probable uptake. Consequently, to investigate their 
localization we increased the treatment concentration to 100 µM. Porphyrin 9 displayed 
the lowest accumulation signal inside the cell, with red luminescent speckles localized 
in the cytoplasm (Figure 34, a). Compounds 20, 16 and 21 showed a similar pattern 
with a diffused and more intense luminescence localized in the cytoplasm and to a very 
minor extent in the nucleoli (Figure 34, b,c, and d, white arrows), as indicated by 
comparison with DAPI staining. The intense red luminescence of 20 suggests that was 
more efficiently taken up inside the cell than the other three compounds used in this 
study. 
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Figure 34: Fluorescence confocal microscopy images showing the pattern of HeLa cells 
incubated for 2 h with a) 100 µM 9, b) 20 µM 20, c) 100 µM 16, and d) 100 µM 21, fixed in 
formaldehyde and stained with mounting solution containing DAPI (Vectashield, 1.5 µg mL
-1
 ). 
White arrows indicate the nucleoli. 
 
2.5.4. DNA BINDING STUDIES 
This work was performed in collaboration with Dr. Anna Leczkowska and Professor 
Ramon Vilar - Department of Chemistry, Imperial College London 
 
Although low nuclear localization was observed for some of the porphyrins, it still 
promoted us to investigate their capacity to bind both quadruplex and duplex DNA. The 
ability of the compounds to recognize and bind to DNA structures such as quadruplex-
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forming sequences (Myc22 and H-telo), and duplex (ds-26) was investigate using 
emission spectroscopy. In Figure 35 the excitation and emission spectra of the studied 
compounds in the absence of DNA are reported. 
 
 
Figure 35: Excitation (dotted) and emission (solid) spectra of 9 (a), 20 (b), 16 (c), 21 (d) in the absence of DNA (the 
spectra are not on the same scales) 
 
In all the cases the interaction with DNA causes red shifting of the excitation/absorption 
bands of each porphyrin, while different changes were observed in the emission 
spectra: no shifting for 9, a blue shift for 20 and a red sift for 16 and 21. The latter may 
be indicative of π - π stacking interactions (Figure 36).  
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 Figure 36: Excitation spectra (dotted) and emission (solid) of the studied compounds in the absence and presence of   
different DNA topologies; (from top) 9, 20, 16 and 21. The intensity of the excitation spectra has been normalized for 
comparison purposes. 
The compounds also display changes in emission intensity upon addition of different 
DNA sequences (Figure 37). 
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                                      Figure 37: Bar chart showing changes in the emission intensity (determinate by 
integration of the emission between λ=600-850 nm) of the compounds (Tris/KCl 
buffer) upon addition of 20 equivalents of Myc22, H-telo,ds-26 and ct-DNA, λex: 
430 nm (9), 430 nm (20), 445 nm (16), 445 nm (21).  
In the case of 20, 16, 21 the enhancement in the emission is more pronounced for the 
quadruplex DNA than ds26. In contrast, 9 do not display selectivity for the quadruplex 
sequences under study versus ds26. We also carried out studies using calf thymus 
(ct)-DNA. The four compounds showed greater enhancement of emission in the 
presence of quadruplex than with (ct)-DNA. The effect of the compounds on the 
thermal stability of Myc22 DNA was further investigated by using variable-temperature 
circular dichroism (CD). The experiments were carried out for Myc22 (5µM) alone and 
in the presence of two equivalents of each compound. Compounds 16 and 21 were 
found to have the greatest stabilization effect on Myc22 (ΔTm =19 and 20 °C for 16 and 
21 respectively). Lower ΔTm was observed for 9 (6 °C) and surprisingly 20 showed no 
stabilization of Myc22. The apparent lack of DNA stabilization by this compound could 
be due to its lower solubility in aqueous media (Figure 38). 
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Figure 38: CD thermal denaturation profiles of Myc22 (5µM) alone and in the presence of 2 equivalents of 9, 20, 16 and 
21. All measurements were carried out in lithium cacodylate buffer (10 mM Li cacodylate, 99 mM LiCl, 1 mM KCl, pH 
7.4); each experiment was performed in triplicate 
 
2.5.5. DNA PHOTOCLEAVAGE 
This work was performed in collaboration with Dr. Riccardo Rubbiani and Professor G. 
Gasser - Department of Chemistry, University of Zurich  
Taking into account the favorable uptake into the nucleus, the interactions with different 
topologies of DNA, and the phototoxic activity of these compounds, we decided to 
investigate their effect on the plasmid DNA upon light irradiation. In these experiments, 
circular plasmid DNA was treated with the target porphyrins and then irradiated. If the 
compounds induce DNA-damage, a decrease in intensity of the supercoiled (intact 
form) band and the formation of single-strand breaks (nick form) or double-strand 
breaks (linear form) bands, which migrate slower in the gel, would be observed. 
Supercoiled pUC18 plasmid was treated with increasing concentrations of the 
porphyrins (0.5-10 µM) and incubated at room temperature for 20 minutes. Then, 
taking advantage of the intense Soret band, we irradiated the samples at 420 nm for 22 
minutes to achieve the same light dose used in the phototoxicity experiments (10 Jcm-
2). A negative control of the plasmid treated with 9, 20, 16, 21 (10 µM) in the dark was 
-21 
 
 
-9 
 
 
-20 
 
 
-16 
 
 
New Porphyrins and Re(I)-Conjugates 
 
48 
 
used for comparative purpose. The complexes were all able to photocleave plasmid 
DNA in a concentration-dependent manner. Notably, 9 and 20 demonstrated a mild 
effect just at 10 µM with attenuation of the supercoiled band and an increase in 
intensity of the nicked band. 16 and 21 showed a marked photocleavage effect already 
at 0.5 µM. This is most likely due to the intercalative potential of the porphyrin core and 
the presence of the three positive charges, which are thought to maximize the DNA-
complex interaction. DNA treated in the dark with the compounds (dark sample) did not 
show any significant alteration of the supercoiled form. Compound 20 showed a shift of 
the supercoiled and niked bands. This effect could be related to the interaction of the 
porphyrin with the plasmid DNA (Figure 39).  
 
 
Figure 39: DNA photocleavage experiments of pUC18 plasmid treated with 9, 20, 16 and 21, in the dark and upon light 
irradiation at 420 nm for 22 minutes (10 Jcm
-2
); untr.= DNA untreated; concentration expressed in µM. 
 
 
2.6. CONCLUSIONS 
 
The results showed that a neutral fourfold-symmetric and a +3-charged tris-
methylpyridiniumporphyrin can bind the fac-{Re(CO)3}
+ fragment in good yields. The 
presence of one or four hydrophilic spacers containing the ethylendioxy groups, as well 
as the positive charges on the complexes contribute to the water solubility of 
compounds 9, 16, 20 and 21. These compounds were evaluated as potential PSs. All 
the compounds are not toxic up to a concentration of 100 µM in the dark on the cell 
lines studied and upon irradiation 9 and 20 showed much better phototoxic properties 
than 16 and 21. Upon Re coordination we observed an enhancement in the phototoxic 
activity of 9 but not for 16. Compounds 16 and 21 were found to be more efficient than 
9 and 20 at binding the DNA (with some selectivity for quadruplex versus duplex) as 
well as in DNA photocleavage. The possibility of obtaining the correspondent 99mTc 
conjugates in order to develop new therapeutic agents is very interesting. 
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2.7. EXPERIMENTAL PART  
 
Mono and bidimensional (H-H COSY and HSQC) NMR spectra were recorded on a 
Bruker 400 or on a Varian 500 spectrometer (500 MHz for 1H, 470 MHz for 19F). All the 
spectra were run at ambient temperature and chemical shifts were referenced to the 
peak of residual non deuterated solvent (δ 7.26 for CDCl3, 3.31 for CD3OD, 2.50 for 
DMSO-d6, 1.94 for CD3CN and 4.79 for D2O). 
19F NMR shifts were referenced to CFCl3 
as internal standard. The UV-Vis spectra were performed at ambient temperature on a 
Jasco V-500 UV-vis spectrophotometer equipped with a Peltier temperature controller, 
using 1.0 cm path-length quartz cuvettes (3 mL). The IR spectra were recorded on a 
Perkin Elmer Spectrum RXI FTIR spectrophotometer. Electrospray mass spectra were 
performed on a Bruker Esquire ESI-MS instrument. ESI HRMS were obtained using a 
Brukner maXis instrument. Column chromatography was performed on silica gel 60 
(Merck,230–400 mesh ASTM), eluting with CH2Cl2/CH3OH mixtures as specified below. 
The reactions were monitored by TLC (silica gel/UV 254, 0.25 mm, glass or aluminum 
support). Re(I) precursor fac-[Re-(CO)3(dmso-O)3](CF3SO3) was prepared according to 
the published procedure [98]. All chemicals were purchased from Sigma–Aldrich and 
used without further purification unless otherwise specified. The porphyrins and their 
Re conjugates precipitate with variable amounts of crystallization solvent, depending 
on the batch. For this reason elemental analysis of such compounds did not afford 
reliable and reproducible results, and the values are not reported here (typically, some 
of the elemental analysis values, especially for C, differ from calculated values by >0.5 
%). Nevertheless, the purity calculated from elemental analysis data was always >95%, 
and the proposed formulae are all consistent with NMR, ESI-MS and ESI HRMS 
spectra. Of note, the 13C NMR spectra are not reported, as the solubility of the 
porphyrins and of their Re conjugates in CD3OD at the maximum extent was 
insufficient to observe all the carbon resonances, especially of the quaternary carbons, 
even after an accumulation time of 72 h. 
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Di-tert-butyl-[1,4,7]-triazacyclononane-1,4-dicarboxylate (diBoc-TACN) (2) 
 
 
 
To a solution of [1,4,7]-triazacyclononane (TACN, 1) (500.5 mg, 3.87 mmol) in CHCl3 
(10 mL) triethyl amine (TEA) (744 µL, 5.4 mmol, 1,4 equiv) was added. To this clear 
solution a solution of (Boc)2O (1.53 g, 7.00 mmol, 1.8 equiv) in CHCl3 (20 mL) was 
added dropwise under an argon atmosphere in 4 h at room temperature, obtaining a 
suspension. The reaction mixture was stirred overnight under an argon atmosphere at 
rt. The reaction was monitored by TLC (EtOAc/EtOH 10:1, Rf = 0.3). The solvent was 
removed under reduced pressure to give the product as white oil. The product was 
dissolved in EtOAc (100 mL) and then washed first with 4% NaHCO3 (100 mL) and with 
brine (100 mL×2). The organic phase was washed with 10% aqueous citric acid (100 
mL×3) and the product moved in the water phase. NaOH 10% was added under ice-
cooling until the water phase was adjusted to pH 10 and the product was extracted with 
CH2Cl2 (100 mL×3). The organic solution was dried over anhydrous Na2SO4 and the 
solvent was removed under reduced pressure to give the product as white oil. 
Yield: 56% (718 mg). 
1H NMR (CDCl3, δ): 3.49 (m, 2H, CH2 c), 3.43 (m, 2H, CH2 c) 3.31 (m, 2H, CH2 b), 3.25 
(m, 2H, CH2 b), 2.94 (m, 4H, CH2 a), 1.48 (s, 18H, CH3 Boc). 
ESI MS m/z: 330.2 [M+H]+, 325.2 [M+Na]+. 
 
1,4-Bis(tert-butyloxycarbonyl)-1,4,7-triazacyclononane-7-benzylacetate 
(diBocTACNCbz) (3) 
 
 
 
 
To a solution of 2 (718 mg, 2.18 mmol) and TEA (608 µL, 4.36 mmol, 2 equiv) in CHCl3 
(12 mL) a solution of benzyl bromoacetate (1.26 g, 5.50 mmol, 2.5 equiv) in CHCl3 (23 
mL) was added dropwise under ice-cooling in 1 h. The solution was stirred for 48 h at rt 
and the reaction was monitored by TLC (CH2Cl2/EtOH 95:5, Rf = 0.6). The solvent was 
removed under reduced pressure to give a yellow oil that was purified by silica gel 
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chromatography (CH2Cl2/EtOH 97:3 then 95:5) to afford the pure product as a yellow 
oil. 
Yield: 89% (926 mg). 
1H NMR (CDCl3, δ): 7.35 (m, 5H, H Ph), 5.13 (t, 2H, CH2 e), 3.49 (s, 2H, CH2 d), 3.45 
(m, 4H, CH2 c), 3.26 (m, 2H, CH2 b), 3.20 (m, 2H, CH2 b), 2.84 (m, 4H, CH2 a), 1.46 (s, 
9H, CH3 Boc), 1.45 (s, 9H, CH3 Boc). 
ESI MS m/z: 478.3 [M+H]+, 500.3 [M+Na]+, 516.3 [M+K]+. 
 
1,4-Bis(tert-butyloxycarbonyl)-1,4,7-triazacyclononane-7-acetic acid  
(2-(diBoc)TACN acetic acid) (4) 
 
 
 
 
To a deoxygenated solution of 3 (926 mg, 1.94 mmol) in CH3OH (25 mL) Pd/C was 
slowly added and then the reaction flask was purged with H2 several times. After 24 h 
of reaction at rt the catalyst was removed by filtration over a celite pad and the solvent 
was evaporated under reduced pressure to give a white crystalline solid. 
Yield: 91.3% (686 mg). 
TLC: CH2Cl2/ EtOH 9:1, Rf = 0.3 
1H NMR (CDCl3, δ): 3.56 ─ 3.18 (m, 8H, CH2 b+CH2 c), 3,39 (s, 2H, CH2 d) 2.77─ 2.65 
(m, 4H, CH2 a) 1.48 (s, 9H, CH3 BOC), 1.49 (s, 9H, CH3 Boc). 
UPLC tr: 1.85 min. 
ESI MS m/z: (negative mode) 386.1 [M–H]-, (positive mode) 388.2 [M+H]+, 410.2 
[M+Na]+. 
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meso-4'-Tetracarboxymethylphenylporphyrin (4'-TCMePP)  
 
To a solution of methyl 4-formylbenzoate  (2.30 g, 14 mmol) in propionic acid (50 mL) 
heated at 140 °C freshly distilled pyrrole (1 mL, 14 mmol, 1 equiv) was added in 
portions. The resulting solution was refluxed for 1.5 h and then cooled at rt and stored 
at -18°C for 12 h. The purple precipitate was removed by filtration, washed several 
times with cold CH3OH and dried under vacuum. 
Yield: 21% (0.63 g). 
TLC: CH2Cl2/EtOH 95:5, Rf = 0.91. 
1H NMR (CDCl3, δ):  8,85 (s, 8H, Hβ), , 8.48 (d, 8H, mPh, J = 8.3 Hz), 8.32 (d, 8H, oPh, 
J = 8.0 Hz), 4.14 (s, 12H, CH3), -2.80 (br s, 2H, NH). 
UV-Vis (CH2Cl2): λmax, (relative intensity, %): 420 (100), 515 (4.0), 550 (2.0), 590 (1.4), 
646 (1.0). 
IR (KBr, cm-1): ν = 3313 (m, NH), 1723 (s, CO), 1276 (s, CO), 1020 (s, CO). 
 
Porphyrin 5 
 
101 mg of 4'-TCMePP (0.12 mmol) were dissolved in a 2:1 THF/CH3OH mixture (100 
mL). 40% KOH solution (w/v) (4 mL) was added and the mixture warmed at 40 °C for 
30 min under magnetic stirring. The reaction was monitored by TLC (CH2Cl2/CH3OH 
9:1, Rf = 0) until the complete disappearance of 4'-TCMePP. At reaction completion, the 
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mixture was acidified to pH 5 with conc HCl and extracted with CH2Cl2 (25 mL×3) after 
addition of water (40 mL). The joined organic fractions were washed with H2O (20 
mL×3) and dried over anhydrous Na2SO4. The solvent was removed under vacuum 
obtaining the product as a purple solid. 
Yield: 91.5% (86.8 mg). 
1H NMR (DMSO-d6, δ):  13.30 (s, 4H, COOH), 8.87 (s, 8H, βH), 8.38 (m, 16H, o+m 
Ph), -2.94 (s, 2H, NH). 
UV-Vis (EtOH): λmax (relative intensity, %): 416 (100), 513 (4.2), 548 (2.1), 590 (1.3), 
646 (0.9). 
 
N-Boc-2,2'-(ethylenedioxy)-diethylamine (6)  
 
To a solution of ethylenedioxy-diethylamine (17.6 g, 0.12 mol, 2 equiv.) in CH2Cl2 (90 
mL)  di-tert-butyl dicarbonate (13.16 g 0.06 mol) in CH2Cl2 (90 mL) was added 
dropwise at 0 °C for 3.5 h, and the reaction mixture was left for other 24 h at rt. The 
reaction was monitored by TLC (CH2Cl2/CH3OH 9:1, Rf = 0.33). The organic phase was 
concentrated and H2O was added (150 mL). The water phase contains the mono 
protected ammine and was extracted with CH2Cl2 (20 mL x 7), instead the organic 
phase contains both the mono- and diprotected ammine. The mixture was purified by 
silica gel chromatography (CH2Cl2/CH3OH, 90:10, then 85:15) to afford the pure mono-
protected amine as a yellow oil. 
Yield: 54% (8.04 g).  
1H NMR (CDCl3, δ):  5.14 (br s, 1H, NHBoc), 3.62 (s, 4H, CH2O), 3.53 (m, 4H, CH2O) 
3.32 (m, 2H, CH2 1), 2.88 (t, 2H, CH2 8),1.44 (s, 9H, CH3 Boc). 
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Porphyrin 7 
 
 
 
 
 
 
36.29 mg of EDCI (0.1893 mmol, 6 equiv) and 25.58 mg of HOBt (0.1893 mmol, 6 
equiv) were added to a solution of 5 (25 mg, 0.0316 mmol) dissolved in 3 mL of 
anhydrous DMF. After stirring for 30 min, 30.35 mg (0.1222 mmol, 4 equiv) of 6 and 
16.99 mg (0.1391 mmol, 4.4 equiv) of DMAP dissolved in 1 mL of anhydrous DMF 
were added. The reaction mixture was shielded from light and stirred at rt for 24 h, and 
then the solvent was removed on a rotary evaporator to yield a dark semisolid. 20 mL 
of H2O were added and the product was extracted with THF/CH2Cl2 1:1 (3×17 mL). The 
organic fraction was evaporated to dryness under vacuum and the resulting solid was 
dried over P2O5. The product was purified by column chromatography (2×20 cm, silica 
gel, CH2Cl2/CH3OH 95:5) obtaining the pure product as a purple solid. 
Yield: 74% (40 mg). 
TLC: CH₂Cl₂:CH₃OH=9:1, Rf = 0.59. 
1H NMR (CDCl3, δ):  8.81 (s, 8H, βH), 8.24 (dd, 16H, 8H mPh + 8H oPh), 7.04 (br s, 
4H, NHCO) 5.04 (br s, 4H, NHBoc), 3.84 (m, 16H, CH2O), 3.73 (m, 16H, CH2O) 3.61 (t, 
8H,CH28) 3.35 (m, 8H,CH21), 1.38 (s, 36H, CH3 Boc), -2.83 (br s, 2H, NH). 
 
Porphyrin 7 · nTFA  
Porphyrin 7 (30.5 mg, 0.018 mmol) was dissolved in CH2Cl2 (2 mL) obtaining a purple 
solution. To this solution TFA (2 mL) was added. The solution was stirred for 2 h 
shielded from light and then the solvent was completely removed under reduced 
pressure to give a blue solid as TFA salt. The reaction is quantitative and the product 
was used in the following step without further purification. 
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Porphyrin 7 as free base 
 
A small amount from the product as TFA salt (20 mg ca.) was dissolved in CH3OH (2 
mL) and neutralized with TEA (2 drops), then it was precipitated with Et2O, filtered, and 
thoroughly washed with Et2O for characterization.  
1H NMR (CD3OD, δ):  3.17 (t, 8H, CH2NH2), 3.80 (m, 40H, CH2O), 8.32 (dd, 16H, mPh 
+ oPh), 8.90 (br s, 8H, βH). 
UV-vis (CH3OH): λmax (ε × 10
-3, dm3 mol-1cm1): 415 (479), 513 (20), 546 (11), 587 (7.1), 
645 (5.9). 
ESI MS m/z: 1312.7 [M+2H]+, 1334.6 [M+H+Na]+, 1350.6 [M+H+K]+. 
 
Porphyrin 8 
 
 
 
 
 
 
 
 
 
To a solution of 4 (54.44 mg, 0.14 mmol, 6 equiv) in anhydrous DMF (3 mL) HOBt 
(28.51 mg, 0.21 mmol, 9 equiv) and EDCI (40.6 mg, 0.21 mmol, 9 equiv) were added. 
The solution was stirred for 30 min, then a purple solution of the porphyrin 7·nTFA 
(0.0234 mmol) and DMAP (28.80 mg, 0.23 mmol, 10 equiv) in anhydrous DMF (4 mL) 
was added. The reaction was monitored by TLC (CH2Cl2/EtOH 9:1, Rf = 0.3). The 
reaction solution was stirred overnight at rt and shielded from light. After removing the 
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solvent, the product was purified by column chromatography (4 x 15 cm, silica gel, 
CH2Cl2/EtOH 90:10 then 85:15) to obtain a purple solid. 
Yield: 66.2% (43.2 mg). 
1H NMR (CDCl3, δ):  8.83 (s, 8H, βH), 8.27 (dd, 16 H mPh + oPh), 7.74 (m, 2H, 
NHCO), 7.66 (m, 2H, NHCO), 7.38 (m, 4H, NHCO ), 3.83 (m, 8H, CH2NH + 8H, CH2O), 
3.72 (m, 16H, CH2O), 3.62 (m, 8H, CH2O), 3.50 (m, 16H, CH2 c + CH2 1), 3.35 (m, 
16H, CH2 b), 3.21 (m, 8H, CH2 d), 2.67 (m, 16H, CH2 a), 1.48, 1,46, 1.42 (s, 72H, CH3 
Boc), -2,78 (br s, 2H, NH). 
UV-Vis (CH2Cl2): λmax, (relative intensity, %): 419.5 (100), 515.2 (4.3), 550.2 (2.1), 
590.2 (1.5), 645.9 (1.1). 
 
Porphyrin 9 
 
 
 
 
 
 
 
 
 
Porphyrin 8 (14.54 mg, 0.0052 mmol) was dissolved in CH2Cl2 (1.5 mL) to obtain a 
purple solution. To this solution TFA (1.5 mL) was added and the solution turned into 
deep green. The solution was stirred for 4h shielded from light, then the solvent and the 
excess of TFA were removed under reduced pressure to give a green-blue product. 
The porphyrin was dissolved in the minimum volume of CH3OH obtaining a deep green 
solution. To this solution 30 μL (0.20 mmol) of TEA were added and the solution turned 
purple. The product was precipitated by adding Et2O dropwise to the solution. The solid 
was extensively washed with Et2O and dried under vacuum. 
Yield: 97.4% (10 mg). 
1H NMR (CD3OD, δ):  8.88 (br s, 8H, Hβ), 8.34 (d, 8H, H Ph, J = 8.2 Hz) 8.30 (d, 8H, H 
Ph, J = 8.2), 3.83 (m, 8H, CH2O), 3.78 (m, 16H, CH2O + CH2NH), 3.73 (m, 8H, CH2O), 
3.64 (m, 8H, CH2O), 3.47 (m, 16H, CH2 d + CH2NH), 3.22 (m, 16H, CH2 c), 3.04 (m, 
16H, CH2 b), 2.86 (m, 16H, CH2 a). 
New Porphyrins and Re(I)-Conjugates 
 
57 
 
UV-Vis (CH3OH): λmax (ε × 10
-3, dm3 mol-1 cm-1): 416 (250), 513 (11), 547 (4.9), 590 
(2.8), 645 (2.4). 
ESI MS m/z: 1989.9 [M+H]+.  
ESI HRMS calcd for [C104H146N24O16]/z:  [M+3H]
3+ 663.37829, found 663.71765; calcd 
for [M+4H]4+ 497.78372, found 498.04085; calcd for [M+5H]5+ 398.42697, found 
398.63419.  
 
meso-5-(4'-Methoxyphenyl)-10,15,20-tris(4'-pyridyl)porphyrins 10 
To a solution of methyl-4-formylbenzoate (1.13 g, 6.88 mmol, 1 equiv) and pyridine 4-
carboxaldehyde (2 mL, 20.65 mmol, 3 equiv) in propionic acid (120 mL) 2 mL of pyrrole 
(27.52 mmol, 4 equiv) were added dropwise. The resulting solution was refluxed at 140 
°C for 2 h and then cooled at rt, then the solvent was partially distilled under reduced 
pressure to 40 mL. After the addition of a mixture of 1:2 ethylene glycol/ CH3OH (60 
mL), the solution it was stored at -4 °C for 72 h. The purple precipitate was removed by 
filtration, thoroughly washed with cold methanol, and dried under vacuum at rt. The 
TLC of the crude product (CH2Cl2/CH3OH 98:2) showed to be a mixture of five possible 
porphyrin isomers: 4'-MPyTrMeP (Rf = 0.77), 4'-trans-DPyDMeP (Rf = 0.55), 4'-cis-
DPyDMeP (Rf = 0.43), 4'-TrPyMMeP 10 (Rf = 0.33) and 4'-TPyP (Rf = 0.13). As only 
one equivalent of methylformylbenzoate was used, the 4'-TMeP isomer (Rf = 0.95) was 
not present in the crude product. 
Chromatographic separation of the mixture of porphyrins 
The isomers were separated by column chromatography. To isolate each isomer it was 
necessary to perform a series of chromatographic separations. After the first 
chromatography (6×20 cm, silica gel, CH2Cl2/CH3OH 99:1 then 98:2) two mixtures (A 
and B) of the following composition were obtained: mixture A (4'-TrPyMMeP 10 and 4'-
TPyP) and mixture B (4'-MPyTrMeP, 4'-cis- and 4'-trans-DPyDMeP and a small amount 
of 4'-TrPyMMeP). 4'-TMeP formed in a very small amount and it was not possible to 
isolate it. 
Mixture A: the chromatographic separation (6 x 20 cm, silica gel, CH2Cl2/CH3OH 98:2) 
gave two pure isomers: 300 mg of TrPyMMeP 10 (absolute yield 6.5%, relative yield 
45.5%) and 110 mg of TPyP (absolute yield 2.2%, relative yield 15%). 
Mixture B: several chromatographic separations were performed to separate the three 
porphyrins. 
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- 4'-TrPyMMeP 10: obtained in pure form after a chromatographic column (5 x 15 
cm, silica gel, CH2Cl2/CH3OH 99:1 then 98:2). During the purification,  a mixture 
made of 4'-cis- and 4'-trans- DPyDMeP 1:1 and a mixture made of 4'-
MPyTrMeP, 4'-trans-DPyDMeP and 4'-cis- DPyDMeP were obtained. 
- 4'-MPyTrMeP was separated from  4'-trans-DPyDMeP and 4'-cis- DPyDMeP by 
a column chromatography (6 x 20cm, silica gel, CH2Cl2 100% then 
CH2Cl2/CH3OH 99:1, 98:2, 97:3). 
- 4'-cis- and 4'-trans- DPyDMeP 1:1 were separated by column chromatography 
(5 x 12cm, silica gel, CH2Cl2 100% then CH2Cl2/CH3OH 99:1, 98:2, 97:3).  
Characterization 
4'-TyP 
1H NMR 4'-TPyP (CDCl3, δ): 9.07 (d, 6H, 2,6py), 8.87 (m, 8H, βH), 8.17 (d, 6H, 3,5py), 
- 2.93 (br s, NH, 2H).  
4'-TrPyMMeP (10) 
1H NMR 4'-TrPyMMeP (CDCl3, δ): 9.06 (d, 2,6py, 6H), 8.87 (m, βH, 8H),8.47 (d, Ph, 
2H),  8.30 (d, Ph, 2H), 8.17 (d, 3,5py, 6H), 4.13 (s, CH3, 3H), -2.89 (br s, NH, 2H).  
4'-cis-DPyDMeP 
1H NMR (CDCl3, δ):  9.04 (dd, 2,6py, 4H), 8.85 (m, βH, 8H), 8.48 (dd, Ph, 4H), 8.31 
(dd, Ph, 4H), 8.18 (d, 3,5py, 4H), 4.12 (s, CH3, 6H), -2.87 (br s, NH, 2H). 
4'-MPyTrMeP 
1H NMR (CDCl3, δ):  9.03 (m, 2H, 2,6py), 8.83 (m, 8H, βH), 8.41 (m, 8H, Ph), 8.27 (m, 
8H, Ph), 8.15 (dd, 2H, 3,5py), 4.12 (s, CH3, 9H), -2.85 (br s, NH, 2H). 
Porphyrin 11 
 
48.70 mg of 4'-TrPyMMeP 10 (0.0721 mmol) were dissolved in a 2:1 THF/CH3OH 
mixture (30 mL). 40% KOH solution (w/v) (6 mL) was added and the mixture warmed at 
40 °C for 5 h under magnetic stirring. The reaction was monitored by TLC 
(CH2Cl2/CH3OH 9:1, Rf = 0) until the complete disappearance of 4'-TrPyMMeP. At 
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reaction completion, the mixture was acidified to pH 5 with conc HCl and extracted with 
CH2Cl2 after addition of H2O. The joined organic fractions were washed with H2O. The 
solvent was removed under vacuum and the product was washed with Et2O and H2O 
and then dried over anhydrous P2O5 obtaining purple-brown solid. 
Yield: 100% (47.71 mg). 
1H NMR (DMSO-d6, δ):  9.05 (d, 6H, 2,6py), 8.90 (m, 8H, βH), 8.37 (dd, 4H, 
oPh+mPh), 8.27 (d, 6H, 3,5py). 
 
Porphyrin 12 
 
21.76 mg of EDCI (0.1135 mmol, 1.5 equiv) and a 15.80 mg of HOBt (0.1169 mmol, 
1.5 equiv) were added to a solution of 11 (50.03 mg, 0.0756 mmol) dissolved in 6 mL of 
anhydrous DMF. To this solution, after stirring for 30 min, 28.16 mg (0.1134 mmol, 1.5 
equiv) of 6 and 10.25 mg (0.0839 mmol, 1.1 equiv) of DMAP dissolved in 2 mL of 
anhydrous DMF were added. The reaction mixture was shielded from light and stirred 
at rt for 20 h and monitored by TLC (CH2Cl2/CH3OH, Rf = 0.4). Then the solvent was 
removed on a rotary evaporator to yield a dark semisolid that was washed with H2O 
and dried over P2O5. The solid was purified by column chromatography (3×15 cm, 
CH2Cl2/CH3OH 97:3 then 95:5). The product was washed with Et2O obtaining the pure 
product as a purple solid. 
Yield: 81% (54.64 mg). 
1H NMR (CDCl3, δ):  9.06 (m, 6H, 2,6py), 8.86 (m, 8H, Hβ), 8.26 (dd, 4H, oPh + mPh) 
8.16 (m, 6H, 3,5py), 7.08 (br s, 1H, NHCO), 5.05 (br s, 1H, NHBoc), 3.87 (m, 4H, CH2 
8), 3.75 (m, 4H, CH2O), 3.67 (m, 2H, CH2O), 3.35 (m, 2H, CH2 1), 1.40 (m, 9H, 
CH3Boc). 
UV-Vis (CH3OH): λmax (relative intensity, %) = 417 (100), 512 (6.1), 547 (1.8), 590 (1.7), 
643 nm (0.7). 
ESI MS m/z: 892.6 [M+H]+, 914.5 [M+Na]+, 930.4 [M+K]+. 
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Porphyrin 13 
 
Porphyrin 12 (54.64 mg, 0.0612 mmol) was dissolved in DMF (5 mL). To this purple 
solution, CH3I (190.81 µL, 3.065 mmol, 50 equivalents) was added and the solution 
was heated at 90 °C under magnetic stirring for 3 h and shielded from light. The 
reaction was monitored by TLC (CH2Cl2/CH3OH, Rf = 0 and CH3CN/KNO3/H2O 4:0.3:1, 
Rf = 0.23). Then the solvent was removed under reduced pressure obtaining a solid 
that was washed with Et2O and CHCl3, and dried under vacuum to give the product as 
a purple solid. 
Yield: 87% (70.12 mg). 
1H NMR (dmso-d6, δ):  9.47 (d, 6H, 2,6py), 9.15 (m, 2H, Hβ), 9.05 (m, 4H, Hβ), 9.00 
(m/t, 6+2H, 3,5py+Hβ), 8.93 (t, 1H, NHCO), 8.34 (dd, 4H, oPh + mPh) 6.80 (t, 1H, 
NHBoc), 4.72 (m/d, 9H, CH3py), 3.73-3.55 (m, 3+1H, CH2O+CH2 8), 3.44 (t, 2H, CH2 
O), 3.11 (m, 2H, CH2 1), 1.36 (m, 9H, CH3Boc), -3.02 (br s, 2H, NH). 
1H NMR (CD3OD, δ):  9.45 (d, 6H, 2,6py), 9.45-8.96 (brs, 8H, Hβ), 8.96 (d, 6H, 3,5py), 
8.29 (dd, 4H, oPh+mPh), 4.81 (m, 9H, CH3py), 3.82 (m, 2H, CH2 spacer), 3.77 (m, 4H, 
CH2 spacer), 3.72 (m, 2H, CH2 spacer), 3.58 (m, 2H, CH2 spacer), 3.20 (m, 2H, CH2 
spacer), 1.36 (m, 9H, CH3Boc). 
UV-Vis (CH3OH): λmax (relative intensity, %) = 424 (100), 516 (7.4), 553 (3.3), 590 (2.8), 
647 nm (1.1). 
ESI MS m/z: 936.4 [M]+, 468.4 [M]2+, 836.5 [M(14)]+.  
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Porphyrin 14 
 
Porphyrin 13 (31.69 mg, 0.0240 mmol) was suspended in CH2Cl2 (3 mL) obtaining a 
brown-green mixture. To this solution TFA (120 µL) was added. The solution was 
stirred for 3 h shielded from light, then the solvent was completely removed under 
reduced pressure to give the product as TFA salt. The product was washed with Et2O 
and 1:1 CH2Cl2/Et2O obtaining a solid color brown-purple. 
Yield: 97.4% (27.49 mg). 
TLC: CH3CN/KNO3sat/H2O 4:0.3:1, Rf = 0.25. 
1H NMR (CH3OD): δ= 9.39 (d, 6H, 2,6py), 9.35─9.01 (br s, 8H, Hβ), 8.97 (d, 6H, 
3,5py), 8.34 (dd, 4H, oPh+mPh) 4.84 (m, 3H, CH3py), 3.90─3.73 (m, 8+2H, CH2O+CH2 
8), 3.18 (m, 2H, CH2 1). 
 19F NMR (CD3CN, δ):  -76.91 (CF3COO
-). 
UV-Vis (CH3OH): λmax (relative intensity, %)= 424 (100), 516 ( 7.4), 553 (3.3), 590 (2.8), 
647 nm (1.1). 
RP-UPLC tr: 1.15 min.  
ESI MS m/z: 836.4 [M]+, 418.1 [M]2+. 
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Porphyrin 15 
 
To a solution of 4 (14.34 mg, 0.0370 mmol, 1.44 equiv) in anhydrous DMF (1.5 mL) 
HOBt (7.52 mg, 0.0556 mmol, 2.17 equiv) and EDCI (10.64 mg, 0.0555 mmol, 2.17 
equiv) were added and the resulting solution was stirred for 30 min. To this solution a 
purple solution of the porphyrin 14 (30.07 mg, 0.0256 mmol) and DMAP (7.65 mg, 
0.0626 mmol, 2.44 equiv) in anhydrous DMF (1.5 mL) was added. The coupling was 
performed in a microwave oven reactor (ramp time: 10 s, hold time: 6 min, T  60 °C, P  
1720 kPa, power 30 W). The reaction was monitored by TLC (CH3CN/KNO3sat/H2O 
4:0.3:1, Rf = 0.38). The charged porphyrin 15 was purified by repeated precipitation 
(CH3OH/Et2O and CH3CN/Et2O) and extensive washing with Et2O and CH2Cl2 to 
remove the excess both of the reagents and of the ligand. 
Yield: 66.4% (26.27 mg). 
1H NMR (CD3CN, δ): 9.12 (m, 6H, 2,6py), 9.07 (m, 6H, βH), 8.95 (m, 2H, βH), 8.82 (m, 
6H, 3,5py), 8.30 (dd, 4H, oPh + mPh), 4.70 (s, 3H, CH3 py), 4.69 (s, 6H, CH3 py), 3.75 
(m, 2H, CH2O), 3.70 (m, 4H, CH2O+CH2NH), 3.65 (m, 2H, CH2O), 3.55 (t, 2H, CH2O, J 
= 5.6 Hz), 3.37 (m, 6H, CH2 NH + CH2 c), 3.23 (m, 4H, CH2 b), 3.09 (m, 2H, CH2 d), 
2.59 (m, 4H, CH2 a), 1.43, 1.42, 1.36 (s, 18H, CH3Boc), -2.96 (s, 2H, NH pyrrole). 
UV-Vis (CH3OH): λmax (relative intensity, %)= 422 (100), 516 (8.3), 553 (3.9), 589 (3.3), 
648 nm (1.3). 
ESI MS m/z: 1205.7 [M]+, 603.1 [M]2+. 
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Porphyrin 16 
 
To a solution of porphyrin 15 was stirred for 3 h shielded from light, then the solvent 
was removed under reduced pressure until the complete elimination of TFA, to give the 
product as TFA salt. The deep green–brown solid was dissolved in CH3OH (1 mL). To 
this solution TEA (10 µL) was added. The product was precipitated by adding Et2O 
dropwise to the solution and was then extensively washed with Et2O. The product was 
obtained as a purple solid. 
Yield: 98% (21.83 mg). 
 TLC (CH3CN/KNO3 sat/H2O 4:0.3:1, Rf = 0.6). 
1H NMR (CD3CN, δ):  9.13 (d, 6H, 2,6py, J = 6.4 Hz), 9.06 (m, 6H, δH), 8.98 (m, 2H, 
bH), 8.83 (d, 6H, 3,5py, J = 6.5 Hz), 8.30 (dd, 4H, oPh+mPh), 7.83 (t, NHCO, 1H, J = 
5.4 Hz), 4.69 (s, 3H, CH3 py), 4.70 (s, 6H, CH3 py), 3.79 (t, 2H, CH2O, J = 5.4 Hz), 3.72 
(m, 4H, CH2O + CH2NH), 3.66 (m, 2H, CH2O), 3.58 (t, 2H, CH2 2, J = 5.5 Hz), 3.37 (s, 
2H, CH2 d), 3.38 (m, 2H, CH2NH), 3.29 (m, 4H, CH2 b), 3.02 (m, 4H, CH2 c), 2.82 (t, 
4H, CH2 a, J = 5.4 Hz). 
19F NMR (CD3CN, δ):  -75.62 (CF3COO
-). 
UV-Vis (CH3CN): λmax (ε x 10
-3, dm3 mol-1 cm-1)= 423 (157), 517 (15), 553 (8.3), 590 
(6.4), 646 nm (3.2). 
ESI MS m/z: 1005.6 [M]+, 502.8 [M]2+. 
ESI HRMS calcd for [C59H65N12O4]/z: [M]
3+ 335.17451, found 335.17451. 
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Porphyrin 17 
 
Porphyrin 12 (20 mg, 0.0224 mmol) was dissolved in CH2Cl2 (2 mL). To this solution 
TFA (500 µL) was added. The solution was stirred for 3 h shielded from light, then the 
solvent was completely removed under reduced pressure to give the product as TFA 
salt. The product was dissolved in CH3OH (600 µL) and neutralized with TEA, 
precipitated and washed with Et2O (3×10mL). 
Yield 100% (17.74 mg) 
TLC: CH3CN/KNO3sat/H2O 5:0.3:1, Rf = 0.30. 
1H NMR (CD3OD, δ):  9.1-8.7 (br s, βH 8H), 8.98 (d, 6H, 2,6Py), 8.29 (m, 10H, HPh + 
3,5 H Py), 3.87-3.75 (m, 10H, CH2O + CH2 8), 3.18 (t, 2H, CH21). 
UV-Vis (CH3OH): λmax (relative intensity, %)= 413 (100), 511 (4.5), 545 (1.4), 588 (1.2), 
642 nm (0.3). 
ESI MS m/z: 792.4 [M+H]+. 
Porphyrin 18 
 
To a solution of 4 (9,36 mg, 0.024 mmol, 1.5 equiv) in anhydrous DMF (1 mL) HOBt 
(4.90 mg, 0.036 mmol, 2.25 equiv) and EDCI (0.036 mmol, 2.25 equiv) were added and 
the resulting solution was stirred for 30 min. To this solution a purple solution of the 
porphyrin 17 (12.75 mg, 0.0161 mmol) and DMAP (4.92 mg, 0.040 mmol, 2.5 equiv) in 
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anhydrous DMF (2 mL) was added. The coupling was performed in a microwave oven 
reactor (ramp time: 10 s, hold time: 6 min, T  60 °C, P 1720 kPa, power 30 W). The 
reaction was monitored by TLC (CH3CN/KNO3sat/H2O 4:0.3:1, Rf = 0.32). Porphyrin 18 
was purified by column chromatography (2×10 cm, CH2Cl2/CH3OH 95:5) obtaining the 
pure product as a purple solid.  
Yield: 70.5 % (13.11 mg) 
1H NMR (CDCl3, δ)  9.06 (d, 6H, 2,6py), 8.86 (m, 8H, βH), 8.28 (m, Ph, 4H),  8.16 (d, 
6H, 3,5py), 7.51 (m, 2H, NHCO),  3.82 (m, 4H, CH2O, CH2NH), 3.71 (m, 4H, CH2O), 
3.63 (m, 4H, CH2O), 3.49 (m, H, CH2N, CH2 TACN), 3.34 (m, 6H, CH2 TACN), 3.20 (m, 
2H, CH2 d), 2.66 (m, 4H, CH2 a), 1.46 (m, 9H, CH3Boc).UV-Vis (CH3OH): λmax (relative 
intensity, %) = 417 (100), 513 (4.3), 547 (1.1), 589 (1.1), 643 nm (0.3).ESI MS m/z: 
1183.6 [M+Na]+, 1161.6 [M+H]+. 
 
Porphyrin 19 
 
To a solution of porphyrin 18 (13.11 mg, 0.0113 mmol) in CH2Cl2 (1 mL) TFA (500 µL) 
was added. The solution was stirred at rt for 3 h shielded from light, and then the 
solvent was removed under reduced pressure until the complete elimination of TFA, to 
give the product as TFA salt. The solid was dissolved in CH3OH (500 µL) and TEA (5 
µL) was added. The product was precipitated by adding Et2O dropwise to the solution 
and was then extensively washed with Et2O. The product was obtained as a purple 
solid. 
Yield: 100% (10.9 mg). 
1H NMR (CD3OD, δ): 8.99 (m, 14H, 2,6py + Hβ), 8.29 (m, 10H, 3,5py + oPh + mPh), 
3.82 (m, 2H, CH2O), 3.78 (m, 4H, CH2O + CH2NH), 3.72 (m, 2H, CH2O), 3.65 (t, 2H, 
CH2O), 3.52 (m, 2H, CH2O),  3.49 (t, 2H, CH2NH), 3.42 (m, 2H, CH2 d), 3.16 (m, 4H, 
CH2 b), 2.95 (m, 4H, CH2 a). 
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UV-Vis (CH3OH): λmax (relative intensity, %)= 413 (100), 510 (5.5), 543 (1.9), 588 (1.8), 
643 nm (0.8).ESI MS m/z: 961.5 [M+H]+. 
 
Re(I)-conjugate 19 
 
Porphyrin 9 (25.08 mg, 0.0126 mmol) was dissolved in anhydrous CH3OH (20 mL). To 
this solution fac-[Re(CO)3(dmso)3](CF3SO3) (49.91 mg, 0.0764 mmol, 6 equiv) was 
added. The stirred mixture was shielded from light and refluxed under argon for 48h. 
The reaction course was monitored by 1H NMR spectroscopy at time intervals (6, 13 
and 30 h) and by TLC (CH3CN/H2O/KNO3, Rf = 0.46). After the solvent was removed 
under reduced pressure, the solid was dissolved in the minimum amount of CH3OH 
and precipitated by adding Et2O dropwise. The product was then extensively washed 
with Et2O and CH2Cl2 to give a brown product. 
Yield: 65% (30 mg). 
1H-NMR (CD3OD, δ):  8.32 (dd, 16H, o+mPh) 8.89 (br s, 8H, βH), 6.83 (s, 8H, NH 
TACN), 4.16 (s, 8H, CH2 d), 3.83 (m, 8H, CH2O), 3.78 (m, 16H, CH2O+CH2NHCO), 
3.72 (m, 8H, CH2O), 3.63 (t, 8H, CH2O, J = 5.5 Hz), 3.44 (t, 8H, CH2NHCO, J = 5.5 
Hz), 3.23 (m, 16H, CH2 a + CH2 TACN), 3.13 (m, 8H, CH2 a), 2.90 (m, 8H, CH2 TACN), 
2.70 (m, 8H, CH2 TACN), 2.59 (m, 8H, CH2 TACN). 
UV-vis (CH3OH): λmax (ε × 10
-3, dm3 mol-1 cm1) 416 (217), 516 (10), 554 (5.0), 596 (3.1), 
649 (2.3). 
ESI HRMS calcd for [C120H170N24O28Re4]/z: [M]
4+ 785.77116, found 785.77425. 
IR (KBr, cm-1): ν =2028 (CO), 1910 (CO). 
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Re(I)-Conjugate 21 
 
Porphyrin 16 (14.32 mg, 0.0106 mmol) was dissolved in anhydrous CH3OH (5 mL). To 
this solution fac-[Re(CO)3(dmso-O)3](CF3SO3) (10.27 mg, 0.0157 mmol, 1.5 equiv) was 
added. The reaction was performed in a microwave oven reactor (first step: T = 65 °C, 
ramp time: 10 min, hold time: 30 s, P = 1720 kPa, power: 25 W; second step: T=110 
°C, ramp time: 10 min, hold time: 10 min, P = 1720 kPa, power: 30 W). The reaction 
was monitored by TLC (CH3CN/KNO3/H2O, 4:0.3:1, Rf = 0.32). The solvent was then 
removed under reduced pressure. The product was dissolved in the minimum volume 
of CH3OH and precipitated with Et2O, then washed with Et2O and CH2Cl2 to remove the 
excess of the complex. 
Yield: 73% (13.76 mg). 
1H NMR (CD3CN, δ):  9.12 (d, 6H, 2,6py, J = 6.2 Hz), 9.06 (m, 6H, βH), 8.98 (m, 2H, 
βH), 8.83 (d, 6H, 3,5py, J = 6.5 Hz), 8.31 (dd, 4H, oPh+mPh), 7.66 (t, NHCO, 1H, J = 
6.2 Hz), 7.12 (t, NHCO, 1H, J = 7.5 Hz), 5.90 (m, 2H, NH TACN), 4.96 (m, 9H, CH3py), 
4.12 (s, 2H, CH2 d), 3.78 (t, 2H, CH2O, J = 5.5 Hz), 3.72 (m, 4H, CH2O+CH2 8), 3.66 
(m, 2H, CH2O), 3.57 (t, 2H, CH2 2 J = 5.5 Hz), 3.38 (m, 2H, CH2 1), 3.31 (m, 2H, CH2 
c), 3.21 (m, 4H, CH2 a), 3.00 (m, 2H, CH2 b), 2.72 (m, 2H, CH2 c), 2.63 (m, 2H,CH2 b). 
19F NMR (CD3CN, δ):  -75.30 (CF3COO
-), -79.28 (CF3SO3
-). 
UV-Vis (CH3CN): λmax (ε x 10
-3, dm3 mol-1 cm-1)= 424 (222), 517 (15), 553 (6.0), 590 
(4.5), 646 nm (0.7). 
ESI HRMS calcd for [C63H71N12O7Re]/z: [M]
4+ 323.62774, found 323.62772.  
IR (KBr, cm-1): ν = 1977 (CO), 2104 (CO). 
 
 
 
 
 
New Porphyrins and Re(I)-Conjugates 
 
68 
 
[Re(CO)3TACN](CF3SO3) (22) 
 
 
 
 
TACN (1.13 mg, 0.0087 mmol) was dissolved in anhydrous CH3OH (2 mL). To this 
solution fac-[Re(CO)3(dmso-O)3](CF3SO3) (5.75 mg, 0.0085 mmol, 0.98 equiv) was 
added. The reaction was performed in a microwave oven reactor (first step: T 65 °C, 
ramp time: 10 min, hold time: 30 s, P 1720 kPa, power: 25 W; second step: T 110 °C, 
ramp time: 10 min, hold time: 10 min, P 1720 kPa, power 30 W). The solvent was then 
removed under reduced pressure to obtain the product as withe solid. 
Yield: 100% (4.8 mg). 
1H NMR (D2O, δ): 3.25 (m, 6H, CH2TACN), 2.99 (m, 6H, CH2TACN).  
ESI MS m/z: 400 [M]+. 
 
Biological methods 
 
Cell culture 
Human cervical carcinoma cells (HeLa) were cultured in DMEM (Euroclone) 
supplemented with 5% fetal bovine serum (FBS, Gibco), 100 UImL-1 penicillin, 100 µg 
mL-1 streptomycin, 2 mM L-glutamine. The non-small-cell lung carcinoma cell line 
(H460M2) was grown in RPMI (Euroclone) supplemented with 5% FBS (Gibco), 
HEPES (Euroclone), 100 UImL-1 penicillin, 100 µg mL-1 streptomycin, 2 mM L-
glutamine. HBL-100 non-tumorigenic epithelial cells were grown in McCoy’s (Sigma) 
supplemented with 10% FBS (Gibco), 100 UI mL-1 penicillin, 100 µg mL-1 streptomycin, 
2 mM L-glutamine. The cells were cultured at 37 °C and in 5% CO2 humidified 
atmosphere. 
 
Cell phototoxicity 
Cells were sown at 10000 per well on 96-well plates and allowed to grow 24 h. Then 
they were incubated for 24 h with 0.1–100 µM solutions of each compound, obtained 
by serial dilutions of stock solutions (freshly prepared in DMSO at a concentration of 
10-2M) with complete medium. Maximum DMSO concentration in the cell incubation 
medium was <_0.3% v/v. Thereafter, the media containing compounds were replaced 
with drug-free medium and cells were irradiated at λ = 650 nm at a fluence rate of 14 
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mW cm-2 for a time such that the total light dose was either 1, 5, or 10 J cm-2 (71 s; 5 
min, 57 s; or 11 min, 54 s). The illumination was performed with a LED board equipped 
with dedicated software. The LED board and software were assembled and set up by 
F. Armani and G. Verona (A.P.L. Laboratory of the Department of Engineering and 
Architecture at the University of Trieste). The LED board is equipped with 96 red LEDs 
(L-53SRC-E, Kingbright) arranged in order to fit with the 96 wells of the cell culture 
plates. The emitted power (mW) at the end of the optical fiber was measured with an 
Ophir NOVA Laser Measurement power meter. Control experiments performed in the 
absence of any photosensitizer indicated that light doses up to 10 Jcm-2 cause no 
evident cell damage. A plate similarly treated, but not exposed to light was used as 
reference for dark cytotoxicity under the same experimental conditions. Analysis of cell 
phototoxicity by MTT assay was performed after further 24 h of incubation and 
compared with the values of control cells without light irradiation. Briefly, MTT dissolved 
in phosphate-buffered saline (PBS, 5 mg mL-1) was added (10 µL per 100 µL medium) 
to all wells, and the plates were then incubated at 37 °C with 5% CO2 and 100% 
relative humidity for 4 h. After this time, the medium was discarded, and 200 µL DMSO 
were added to each well according to the method of Alley et al.[99] Absorbance units 
were measured at λ = 570 nm on a SpectraCount Packard instrument (Meriden, CT, 
USA). IC50 values were calculated from dose–effect curves and are the mean +_SD of 
at least three separate experiments. The fitting procedure applied is a nonlinear 
regression performed with GraphPad Prism version 6 for Mac OS X version 6.0b 
(GraphPad Software, San Diego, CA, USA). Experiments were conducted in 
quadruplicate and repeated thrice. 
 
Statistical analysis 
 Data obtained in the experiments were subjected to statistical analysis of variance 
(ANOVA) and Tukey–Kramer post-test, or to unpaired t test performed using GraphPad 
InStat version 3.06 for Windows (GraphPad Software, San Diego, CA, USA).  
 
Singlet oxygen production 
The quantum yield (ΦΔ) of singlet oxygen generated by compounds 9, 16, 20, 21 upon 
photoexcitation was measured using 9,10-dimethylanthracene (DMA) as substrate. 
Typically, 3 mL of 0.133 mM CHCl3 solution of DMA and 0.4 µL solution of the 
porphyrin (0.4 A at Soret band maximum, ≈ 10 mM) in DMSO were placed in a 
luminescence quartz cuvette of 1 cm optical path and irradiated in a RPR100 Rayonet 
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Chamber Reactor (Southern New England Ultraviolet Company) complete with two 
lamps of λ = 420 nm light for different periods of time. The fluence rate was 2.57 mW 
cm-2. The first-order rate constant of the photo oxidation of DMA by 1O2 was obtained 
by plotting A0-A as a function of the irradiation time t, in which A0 and A represent the 
absorbance intensity at time 0 and at time t, respectively. The rate constant was then 
converted into 1O2 quantum yield by comparison with the rate constant for DMA photo-
oxidation sensitized by TPP, (for which ΦΔ was shown to be 0.55) and with the 
absorbance correction factor I=I0*(1-10-Aλ), where I0 is the light intensity of the 
irradiation source in the irradiation interval, and A is the absorbance of the sample at 
wavelength λ. 
 
Fluorescence microscopy 
Cells were grown on 18 mm Menzel glass coverslips (Menzel, Germany) at a density of 
2.5 x 105 cells mL-1 and incubated with the indicated compound. Upon 2 h treatment, 
cells were fixed for 15 min at room temperature in 4% formaldehyde solution (4% 
formaldehyde (w/v) in 1 x PBS) and mounted on microscopy slides. Fixed cells were 
examined with a CLSM Leica SP5 confocal microscope (DAPI λe x= 405 nm, λem = 430–
500 nm; porphyrin λex = 514 nm, λem = 600–700 nm) using 63 x 1.20 oil-immersion 
lenses. 
 
DNA preparation 
All oligonucleotides, namely Myc22 (5’-TGA GGG TGG GTA GGG TGG GTA A-3’), H-
telo (5’-AGG GTT AGG GTT AGG GTT AGG G-3’), and ds-26 (5’-CAA TCG GAT CGA 
ATT CGA TCC GAT TG-3’) were purchased from Eurogentec and used without further 
purification. ct-DNA was purchased from Sigma–Aldrich and used as received. The 
oligonucleotides (for both emission and CD spectroscopic studies) were dissolved in 
Milli-Q water to yield 1 mM stock solution which was stored at – 20 °C and defrosted on 
the day when a given experiment was carried out. The 1 mm oligonucleotide stock 
solution was further diluted using appropriate buffer to the desired concentration on the 
day of the experiment. The concentration of oligonucleotides was determined by UV-
Vis spectroscopy using appropriate extinction coefficients at λ = 260 nm. For the 
emission titrations, concentration of the compound being studied was kept constant (at 
5 µm); the concentration of DNA added during the titrations (after appropriate dilutions 
from the stock solution) ranged between 0 and 40 µm. For the variable-temperature CD 
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spectroscopic studies the final concentrations of DNA and compound were 5 and 10 
µm, respectively. 
 
 
Compound preparation for DNA binding studies 
Compounds were dissolved in Milli-Q water to yield 1 mM solutions (except for 2, which 
was dissolved in DMSO). These solutions were diluted with the buffer to give a final 
concentration of 5 µm for the emission titrations and 10 µm variable-temperature CD 
studies. Unless stated otherwise, all measurements were performed in Tris・HCl (50 
mM) buffer containing 100 mm KCl (pH 7.4). Emission and excitation spectra were 
recorded on Varian Cary Eclipse Spectrometer. Circular dichroism measurements were 
carried out using a Jasco J-715 Spectropolarimeter. 
 
DNA photocleavage 
DNA photocleavage experiments were performed according to a method reported 
recently by Gasser’s group [100]. More specifically, supercoiled pUC18 plasmid (0.20 
µg) was incubated with 1–4 at increasing concentrations in buffer (50 mM Tris・HCl, 
18 mM NaCl, pH 7.2) and at λ = 420 nm for 22 min (10 J cm-2) in a RPR100 Rayonet 
Chamber Reactor (Southern New England Ultraviolet Company). A series of negative 
controls of the plasmid treated with the highest concentrations of 1–4 in the dark was 
used for comparative purposes. After irradiation the samples were added with loading 
buffer (250 mg xylene cyanol in 33 mL 150 mM Tris・HCl buffer, pH 7.6) and analyzed 
by electrophoresis in agarose 0.8% in 1_TBE (diluted from a 10_ solution of 108 g Tris
・HCl, and 55 g of H3BO3 in 900 mL H2O) at 70 V (BioRad Power Pack 1000) for 1.5 
h. The gel was pre-stained with GelRed (1:10 000, Biotium), photographed and 
quantified with an AlphaDigiDoc 1000 CCD camera (Buchner Biotec AG) and 
AlphaImager software (version 1.3.0.7.). 
 
3.  
SYNTHESIS OF PEPTIDE- 
PHOTOSENSITERS TO TARGET 
PROSTATE CANCER CELLS 
 
 
This work is in collaboration with the research group of Professor Gilles Gasser – 
Department of Chemistry, University of Zurich 
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3.1. TARGETING CANCER CELLS 
 
Targeted drug delivery methods have been explored to improve drug efficacy and 
reduce side effects by directing the drug to a specific cell type. Many molecules have 
been studied to target drugs such as monoclonal antibodies, nanoparticles, folate 
ligands and peptides. The concept of drug-carriers conjugates is illustrated in Figure 40 
[101]. 
 
Figure 40: The structure of a drug-linker-peptide conjugate [101] 
Peptides are deeply investigated since they have advantages that make them excellent 
candidates for drug targeting such as: i) increased tissue permeability; ii) rapid 
internalization capacity; iii) effective receptor binding; iv) rapid clearance; v) very mild 
antigenicity [102]. Peptides present also negative factors such as short biological half-
life and loss of binding affinity upon coupling with a chelator that can be minimized by 
inserting a spacer between the binding sequence and the chelating moiety [103]. The 
treatment of cancer has been enhanced with targeting drug delivery methods exploiting 
for example specific targets receptors overexpressed in tumor cells [104]. Focusing on 
photodynamic therapy (PDT), a third generation of PSs is being investigated to 
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enhance the tumor selectivity by using additional molecular entities capable to address 
the PSs to a specific target [105]. In this way PDT can overcome the low tumor 
selectivity of the clinically used PSs. Since porphyrins are preferentially but not 
selectively accumulated in tumor tissues, Vicente and coworkers synthetized several 
peptides-porphyrins to increase the tumor selectivity. The selective accumulation of 
these porphyrin-peptides depends on the type of targeting peptide bound to the 
porphyrin. For example the cell-penetrating peptides (CPPs) increase the penetration 
of the porphyrin into the cell; instead the mitochondrial localization signals (MLSs) 
increase the accumulation in the mitochondria [106-109]. The CPP-conjugate, reported 
in Figure 41 is more selective for prostate tumor than hematoporphyrin derivative 
(HPD) [110]. 
 
                  Figure 41: Vicente’s porphyrins containing a peptide sequence CPP based on the HIV-1 Tat sequence 
Besides CPPs also the membrane translocation sequences (MTSs) are used to target 
the tumor cells. CPPs and MTSs are peptides with a maximum of 30 amino acids that 
are able to translocate across the biological cell membranes. Their cell membrane 
penetration mechanism is not fully understood. However it seems to depend on the 
type of peptide and it is probably an endocytic mechanism [111, 112]. Instead the 
synthetic peptides containing a nuclear localization signal sequence (NLS) are peptides 
that bind DNA after cell penetration via receptor-mediated endocytosis. The resulting 
DNA–NLS complex can be recognized by specific intracellular receptor and proteins 
[113]. Peptides that target the vascular system are also studied to increase the 
selectivity of the PS. Also the second generation of radiopharmaceuticals is based on 
targeted drug delivery methods. Several researches focused on the development of 
new tumor specific peptide based radiopharmaceuticals [103, 114]. To be clinically 
useful for tumor imagining, a radiolabeled peptide should have: i) high affinity for the 
target receptor; ii) ease of preparation; iii) high stability in vivo; iv) high specific uptake 
and retention in tumors [103, 114]. The structure of a targeting peptide 
radiopharmaceutical is illustrated in Figure 42. 
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Figure 42: A general strategy to target a receptor with a peptide radiopharmaceutical   [103] 
An important example of targeting peptide, especially in the field of 
radiopharmaceutical, is represented by bombesin (BN), a 14-amino acid neuropeptide 
isolated from the skin of the Bombina orientalis frog. Its structure (a COOH terminus 
ending in Gly-His-Leu-Met-NH2) is well known and is reported in Figure 43 [115]. 
 
Figure 43: Peptide sequence of bombesin BN and BN[7-14] 
Two related peptides, the gastrin-releasing peptide (GRP) and the neuromedin-B 
(NMB), are present in humans [114]. GRP is made of 27 amino acids and shares with 
BN the seven COOH terminal amino acids; instead NMB is made of 10 amino acids 
and present a COOH terminus ending in Gly-His-Phe-Met-NH2. To date, three 
mammalian BN/GRP receptor subtypes were characterized for these peptides: i) GRP-
R or BB2-R (GRP-preferring receptor); ii) NMB-R or BB1-R (NMB-preferring receptor) 
and iii) an orphan receptor called BRS-3 or BB3-R.  These are heptahelic G protein-
coupled membrane receptors, which stimulate many signals; in particular they activate 
phospholipase C and MAP kinase, stimulate tyrosine phosphorylation and rarely 
adenylate cyclase [116, 117]. After activation, they undergo a number of receptors 
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modifications including phosphorylation, internalization and recycling, down regulation 
and desensitization. Researchers are interested in two signals cascades especially in 
tumor tissues: the tyrosine kinase cascades and the epidermal growth factor receptor 
(EGFR) (Figure 44) [118].   
 
 Figure 44: General transduction of G-protein-coupled receptors GPCRs (A) and BN receptors (B) [114] 
GRP and NMB are distributed in both central and peripheral nervous system of 
mammals; indeed they are involved in several physiological processes such as 
circadian rhythm, TSH release, behavior control, thermoregulation, satiety, and in the 
urogenital, respiratory and immune systems. They are important especially in the 
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gastrointestinal (GI) tract where they stimulate the gastrin release and regulate gastric 
acid secretion and enteric motor function. Furthermore, since these receptors are 
overexpressed in several tumors, GRP and NMB stimulate the growth and the 
differentiation of tumors such as colon, prostate, lung, head and neck, CNS, pancreatic 
and some gynecologic tumors. These peptides have effect also in the premalignant 
cells of prostate, gastric and lung cancers [119]. For such a reason, their receptors are 
promising targets for the cancer therapy and BN-like peptides are excellent molecules 
to deliver drugs into tumor cells [120]. Going into detail about the structure-activity 
relationship (SAR) of the BN-like peptides, the C terminus of BN is required for high 
affinity binding and its BN[7-14] fragment is the minimum sequence required to 
stimulate the receptor activity (Figure 43). More specifically GH(L/F)M-NH2 are the 
amino acids of the carboxylic terminus of bombesin, GRP and NMB required for the 
activity [121, 122]. Concerning the receptor, four amino acids of the gastrin releasing 
peptide receptor were proposed by Battery and co-workers as important for a high 
binding affinity: Gln-121, Arg-288, Ala-308 and Pro-199 [122]. With the aim to treat the 
tumors already cited, BN and GRP agonists are used, and recently also their 
antagonists were taken into account since they can provide antitumor effect [114, 123]. 
Although antagonists are not internalized into tumor cells after binding to the receptors, 
they offer excellent targeting properties. BN[7-14]  was studied to evaluate the 
transport of metals such as ruthenium into tumor cells [124], and the same peptide was 
conjugate with radioactive metals such as 105Rh, 99mTc, 111In, 177Lu, 18F, 64Cu showing 
promising results as tumor localizing agent [118]. For example the bombesin 
analogues 177Lu-AMBA and Re(CO)3/
99mTc(CO)3 BBS-II were synthesized and 
evaluated in vitro in PC-3 cell cultures (Figure 45) and 177Lu-AMBA showed high affinity 
and specificity for the GRP-R and it bounds this receptor with a nanomolar affinity. 
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Figure 45: 
177
Lu-AMBA and Re(CO)3BBS-II structures 
 
3.2. STRATEGIES FOR THE DEVELOPMENT OF NEW 
PHOTOSENSITIZERS  
 
For all the reasons detailed above we designed a new tumor-specific PS, according to 
the synthetic strategy showed in Figure 46. The structure is formed of several parts 
bound together by covalent bonds. The main portions are a porphyrin, a targeting 
peptide sequence and a chelator suitable for metal coordination. 
 
 
 
 
 
 
 
 
 
Figure 46: Schematic structure of the designed molecule 
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Porphyrin 14 (Scheme 9) was chosen since it is water soluble and it can easily bind a 
chelator unit in one peripheral position. The tridentate chelator unit is the functionalized 
TACN 4 (Scheme 9) that can coordinate ReI/99mTcI fragments, such as 
{Re/99mTc(CO)3}
+. Bombesin BN[7-14] (Scheme 9) was chosen as a targeting peptide 
for three reasons: i) it can target prostate cancer cells, a tumor already treated with 
PDT in clinical practice; ii) its coupling with a functionalized chelator (NOTA) is 
described [125]; iii) it is in clinical trials for prostate cancer [126]. Consequently, this 
very challenging molecule might act as a PS, be selectively targeted to prostate cancer 
cells and be able to coordinate both cold Re and hot 99mTc in order to have a potential 
application also in the diagnostic field. Two different synthetic approaches based on 
click chemistry and coupling reaction are described in the following sections.  
 
3.3. CLICK CHEMISTRY APPROACH FOR THE SYNTHESIS OF             
BN [7-14]- PORPHYRIN  
3.3.1. FIRST STRATEGY FOR THE SYNTHESIS OF THE FINAL MOLECULE 
The first synthetic approach to bind the three parts of the molecule (porphyrin, peptide 
and chelator) was planned by using a click chemistry reaction. The key molecule of the 
synthesis is the commercially available Boc-propargyl-Gly-OH. This compound has 
either i) a carboxylic group, that can react with the amino group of porphyrin 14; ii) an 
amino group, that can form an amide bond with the carboxylic group of the 
functionalized TACN 4; and iii) an alkyne suitable to the click reaction. An azido 
function was introduced on the BN[7-14] by reacting  5-azidopentanoic acid with the 
amino group of the glutamine in position 7 of the peptide sequence, thus making 
possible the click chemistry reaction between the peptide and  the porphyrin (Scheme 
9). 
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Scheme 9: Synthetic strategy to connect 14, 4 and BN[7-14] using Boc-propargyl-Gly-OH  
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3.3.2. SYNTHESIS OF THE ALKYNE-PORPHYRIN AND THE AZIDO PEPTIDE  
Porphyrin 14 was first coupled with the Boc-propargyl-Gly-OH and then with the 
functionalized TACN 4 following the procedure showed in Scheme 10.  
 
Scheme 10: Synthetic route for 22-24. Reagents and conditions: a) DMAP, EDCI, HOBt, DMF, overnight, rt, 69%;   b) 
TFA, CH2Cl2, 4h, rt; c) DMAP, EDCI, HOBt, DMF, overnight, rt, 70% 
The first coupling reaction between the amino group of porphyrin 14 and the carboxylic 
group of Boc-propargyl-Gly-OH was performed using EDCI, HOBt and DMAP in DMF 
at room temperature overnight. After the purification by repeated precipitations 
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(CH3OH/Et2O) and extensive washes with Et2O and CH2Cl2, the product was obtained 
in high yield. The amino group of the Boc-propargyl-Gly-OH was deprotected using 
TFA in CH2Cl2 and porphyrin 24 was obtained as TFA salt and then directly reacted 
with the carboxylic group of the chelator. After the usual workup of precipitations and 
washes, porphyrin 25 was obtained and characterized by RP-UPLC-MS, 1H and HSQC 
NMR. The downfield region of the 1H NMR spectrum (Figure 47) shows the pyridine 
protons at δ 9.39 (2,6py) and 8.97 (3,5py) (cross peaks in the HSQC spectrum at δ 145 
and δ 133), and the 4H of the phenyl ring at δ 8.30 (cross peaks at δ 126 and 135 in 
the HSQC spectrum). In the upfield region the resonance of the CH3 protons bound to 
the pyridines (δ 4.80, cross peak at δ 48 in the HSQC spectrum) is superimposed on 
the H2O resonance. The protons of the spacer resonate as a cluster of multiples 
between δ 3.41 and 3.82 (cross peaks at δ 70 for the protons bound to an oxygen atom 
and δ 40 for the ones bound to a nitrogen atom in the HSQC spectrum) (Figure 48). 
The protons in position 2' and 5' of the glycine resonate at δ 4.51 (cross peak at δ 52 in 
the HSQC spectrum) and at δ 2.36 (cross peak at δ 72 in the HSQC spectrum) 
respectively. The protons in position 3' of the glycine overlap with Ha of TACN and 
resonate as a multiplet. This assignment was confirmed by the HSQC spectrum that 
showed two cross peaks at δ 54, for the Ha protons of the chelator, and at δ 22 for the 
3' protons of the glycine. Between δ 3.5 and 3.1 the spectrum shows the multiplets of 
Hb, Hc and Hd protons of TACN and the protons of a CH2 bound to a nitrogen atom of 
the spacer.   
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Figure 47: 
1
H NMR (CD3OD) of 25 
 
Figure 48: HSQC (CD3OD) of 25 
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The azido-peptide BNN3 (Scheme 15) was synthesized by solid-phase peptide 
synthesis (SPPS). Tentagel-S-RAM was used to build up the peptide sequence BN[7-
14]. This is a low cross-linked polystyrene resin on which a poly(ethylene glycol) is 
grafted via an ether bond, which has high stability towards acid treatment and 
minimizes PEG leaching (Figure 49). Thanks to the PEG chains the resin solubilizes 
both hydrophobic and hydrophilic compounds and it is stable to pressure [127]. 
 
 
Figure 49: TentaGel and Tentagel-S-RAM resins 
The peptide was synthesized following these steps: 
1) Swelling of the resin 
The resin was left shaking in DMF for at least 1 h before use in order to open the resin 
beads and to allow the Fmoc amino groups of the resin to be available for the coupling 
reaction with the first amino acid (methionine). After filtration, the resin was ready for 
the second step. 
2) Deprotection of the NHFmoc  
The Fmoc deprotection was performed with piperidine in DMF [128]. 
3) Activation of the carboxylic group and coupling reaction 
The activation of the carboxylic group of the first amino acid was performed using a 
large excess of TBTU in DMF [128-132].  
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4) Reaction control 
A Kaiser test was performed to evaluate the reaction completion. A positive result 
(yellow Kaiser test solution) indicated that no free amino group was present on the 
resin. Steps 2 and 3 were repeated for the second amino acid of the sequence and so 
on for the other amino acids of the target peptide. A negative result (dark blue Kaiser 
test solution) indicated that Fmoc amino groups were still present on the resin, and 
step 2 and 3 were repeated for the same amino acid.  
5) Cleavage reaction 
This step was performed both to check the coupling reaction before performing other 
reactions in solid phase (SP) and to completely release the peptide from the resin in 
order to carry out other reactions in solution. After the peptide synthesis completion, 
the peptide was cleaved from the resin using a cleavage solution made of TFA, TIPS 
and H2O. The TFA was used both to release the peptide from the solid support and to 
remove the protecting groups of the side chains of the amino acids (Scheme 11). It is 
convenient that the protecting groups of the side chains are released with the same 
reagent (TFA) used to release the peptide from the solid support [133]. Secondary 
reactions can occur during the deprotection and cleavage steps, since the carbocations 
that are formed during the reaction can react with the side chains of the peptide. For 
this reason TIPS is usually added as scavenger to the cleavage solution. The filtrate 
containing the deprotected and cleaved peptide was evaporated and the peptide was 
precipitated and washed several times with cold Et2O. The peptide was purified by 
HPLC and characterized by RP-UPLC-MS and analytical HPLC.  
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Scheme 11: Cleavage reaction of the peptide 
The whole peptide BN[7-14] synthesis is reported in Scheme 12. A large excess of 
each amino acid was used and after every coupling reaction the peptide was purified 
simply by filtration, increasing the yield and reducing the reaction time.  
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Scheme 12: Synthesis of BN[7-14]. Reagents and conditions: a) piperidine, DMF, 2'+10'; b) TBTU, DIPEA, 2,6-lutidine, 
DMF, amino acid, 1h, rt. 
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The following step was the SP coupling reaction between the TBTU-activated 
carboxylic group of the azido pentanoic acid and the amino group of the glutamine of 
BN[7-14] that was previously deprotected (Scheme 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Scheme 13: Synthesis of BNN3. Reagents and conditions: a) piperidine, DMF, 2'+10';                         
b) TBTU,   DIPEA, 2,6-lutidine, DMF, 1h, rt 
Both BNN3 and the correspondent BNN3 with methionine oxidized (BNN3 OX) were 
observed in RP-UPLC-MS chromatogram (Figure 50). 
r 
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Figure 50: RP-UPLC-MS (H2O/ACN) of BNN3, 290 nm 
The oxidation of methionine to sulfoxide (Figure 51) is a reaction that can occur during 
extraction and storage, in the presence of biological oxidants (NAD) and also in an 
acidic environment. In fact oxygen-exchange reactions can occur in strong acids or in 
the presence of copper or iron ions that are biological species [134-136].  
 
Figure 51: Oxidized forms of methionine 
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3.3.3. CLICK CHEMISTRY REACTION 
 
A click chemistry reaction must meet the several requirements. It should: i) start from 
few small molecules; ii) use easily removed and environmentally friendly solvents such 
as water; iii) give high yield and iv) give products that can be purified with easier 
methods than chromatography [137]. The copper catalyzed azide-alkyne cycloaddition 
reaction (CuAAC) perfectly satisfies the requirements of this synthetic approach [138]. 
Thanks to the copper catalysis, the reaction occurs at room temperature in water and a 
single product is formed in high purity. A simplified mechanism of the CuAAC is 
reported in Scheme 14. The electrons of the Cu(I) coordinate the ones of the alkyne, 
then the azide can easily attack the alkyne, giving the triazole ring. 
 
    Scheme 14: Simplified mechanisms of the CuAAC reaction                                                                                 
The most critical aspect of this reaction is to maintain a high amount of Cu(I) during the 
whole reaction, as Cu(I) is easily oxidized to Cu(II). For this reason it is convenient to 
use a source of Cu(II) (for example copper sulfate) and to generate Cu(I) in situ by a 
reducing agent (for example sodium ascorbate).  
The reaction between porphyrin 25 and BNN3 was performed in different experimental 
conditions (Table 3). All the reactions were performed under a nitrogen atmosphere to 
avoid copper oxidation. In trials 1 and 2 porphyrin 25 was used in SP and the resin was 
washed with a solution 0.1 M of EDTA that should remove the copper that was possibly 
inserted into the porphyrin ring [139]. Trial 3 was performed in solution using porphyrin 
25, since [Cu(CH3CN)4]PF6 should avoid the insertion of the copper into the porphyrin 
ring [140]. Trial 4 was performed in solution using the zinc porphyrin 26. 
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Trial 
number 
Type of 
synthesis 
Reactive Conditions 
Mass values 
from 
RP-UPLC-MS 
 
1 
 
SP 
 
25, CuI, TBTA [141] 
 
DMF, overnight, rt 
 
BNN3, BNN3 ox 
 
2 
 
SP 
 
25, CuI, DIPEA [142] 
 
 
DMF, overnight, rt 
 
BNN3, BNN3 ox 
 
3 
 
solution 
 
25,[Cu(CH3CN)4]PF6,TBTA[143] 
 
H2O/tBuOH, 48 h, rt 
 
Cu-25 
 
4 
 
solution 
 
26, Na ascorbate, CuSO4 
 
H2O/tBuOH, 64 h, rt 
 
26,BNN3,BNN3ox 
 
Table 3: Trials for the click chemistry reaction between porphyrin 25 or 26 and BNN3. When the reaction was performed 
in solution, the mmol of BNN3 were calculated from the law of Lambert-Beer, using the ε value of the tryptophan in 
aqueous solution: 5690 cm
-1
M
-1
 [144]. 
The insertion of zinc ensures that the porphyrin 25 will not coordinate the copper during 
the reaction. Furthermore, zinc should not reduce the efficacy of the molecule as PS 
since several zinc-porphyrins revealed good photoactive properties [145]. Porphyrin 25 
was reacted with a large excess of zinc acetate dihydrate for 2 hours at room 
temperature to give porphyrin 26 (Scheme 15). 
 
 
 
 
 
 
 
 
Scheme 15:  Synthetic route for 26. Reagents and conditions: CH3OH, 2h, rt 
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The reaction was monitored by UV-vis since after metal insertion only two Q bands are 
observed between 500 and 700 nm (Figure 52).  
 
Figure 52: UV-vis (CH3OH) of 25  
As the product 26 is water soluble, it was not possible to purify it from the excess of 
zinc acetate which however should not interfere with the following click chemistry 
reaction. The RP-UPLC-MS analysis showed that the product was substantially pure 
(Figure 53).  
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Figure 53: RP-UPLC-MS (CH3OH) of 26, 440 nm 
Since the attempts of click chemistry between the porphyrin 25 or 26 and BNN3 in SP 
and in solution were unsuccessful, we studied a model reaction between zinc porphyrin 
26 and the azido pentanoic acid in solution (Scheme 16) [146, 147].  
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  Scheme 16: Synthetic route for 27. Reaction conditions: CuSO4, Na ascorbate, H2O/tBu, 22h, rt; then 30' 85 °C MW 
 
26 was reacted in solution with 2.6 equivalents of azido pentanoic acid in the presence 
of 2 equivalents of sodium ascorbate, 0.6 equivalents of copper sulphate in 1:2 
H2O/tBu and the solution was left stirring at room temperature shielded from light. The 
reaction was monitored by TLC (CH3CN/KNO3 sat/H2O 4:0.3:1) and RP-UPLC-MS. 
After 22 hours of reaction product 27 and the unreacted 26 were observed from the 
RP-UPLC-MS analysis (Figure 54).  
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Figure 54: RP-UPLC-MS (H2O/ACN) of 27 after 22h of reaction, 446 nm  
 
In order to improve the yield of 27, the reaction mixture was heated in a microwave 
reactor for 30 minutes at 85 °C [148].  A large excess of the azide was used to bring 
the reaction to completion. As it can be observed from the RP-UPLC-MS in Figure 55, 
the chromatogram shows the peak of 27 at 1.9 minutes of retention time and no 
starting material was observed.  
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Figure 55: RP-UPLC-MS (H2O/ACN) of 27 after 22 h + 30' MW, 436 nm 
 
As the formation of 27 was observed in the model reaction, the click chemistry reaction 
between porphyrin 26 and BNN3 was performed in solution using microwave 
irradiation. The experimental conditions (reaction time and equivalents) used for the 
synthesis of 27 were optimized for the synthesis of 28. A solution of zinc porphyrin 26, 
BNN3, a large excess of copper sulfate and sodium ascorbate in 1:2 H2O/tBu was 
directly heated in a microvave reactor at 85 °C for 1h obtaining a precipitate and a 
green solution (Scheme 17).  
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Scheme 17: Synthetic route for 28 and 29. Reaction conditions: a) CuSO4, Na ascorbate,1:2  H2O/tBu, 1 h MW; b) TFA, 
2h, rt; c) TEA, CH3OH 
 
From the RP-UPLC-MS analysis a mixture of 28 and unreacted BNN3 was observed 
along with the correspondent oxidated forms. The RP-UPLC-MS analysis of the 
reaction mixuture presents two broad peaks at retention time 1.8 minutes and 1.9 
minutes. The first one is a superimposition of BNN3 2 OX (azido peptide with the sulfur 
oxidated to sulfon) with 28 OX, and the second one is a superimposition of BNN3 OX with 
28. The peak at retention time 2.1 min is related only to BNN3 and for this reason the 
UV absorption was observed only at 275 nm (Figure 56). 
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Figure 56: RP-UPLC-MS (H2O/ACN) of 28, 443 nm and 275 nm 
 
The solvent was evaporated and 28 was treated with TFA for 2 hours at room 
temperature, then the TFA was evaporated and the solid was treated with TEA 
(Scheme 16). The crude product was purified by semipreparative HPLC and the most 
consistent and pail purple peak absorbing at 400 nm was collected.  From the RP-
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UPLC-MS analysis the product 29 2 OX was observed with an acceptable degree of 
purity (Figure 57).  
 
 
Figure 57: RP-UPLC-MS (H2O/ACN) of the purified 29, 427 and 254 nm 
Due to the difficulty of the HPLC purification a very low quantity of the product was 
obtained. This is in agreement with the crowded RP-UPLC chromatograms of both the 
crude 28 and 29. For this reasons a different synthetic route was explored.  
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3.4. COUPLING REACTION APPROACH FOR THE SYNTHESIS OF THE 
BN[7-14]- PORPHYRIN  
3.4.1. SECOND STRATEGY FOR THE SYNTHESIS OF THE FINAL MOLECULE  
In this synthetic strategy Fmoc-Lys(Mtt)-OH was used as key molecule to connect 
BN[7-14], porphyrin 14 and the chelator 4 by using conventional coupling reactions. 
The commercially available Fmoc-Lys(Mtt)-OH was chosen since it has three functional 
groups, a carboxylic group and two differently protected amino groups, namely  a 
NHFomc in α position and a NH-4'methyltrilyl (NHMtt) in ε position (Scheme 18). As the 
two amino groups are deprotected in different environments (basic for the NHFomc and 
acidic for the NHMtt), a different coupling reaction can be performed on each amine. In 
peptide chemistry the Mtt group is used as it can be selectively removed to allow 
further modifications of the amino acid side chains of the peptide, such as lysine [98]. 
According to the synthetic strategy, the carboxylic group of the Fmoc-Lys(Mtt)-OH was 
coupled to the glutamine of the BN[7-14] sequence and, after a first deprotection step, 
the amino group in ε position was coupled to the functionalized TACN 4. After the 
deprotection, the α-amine was coupled with porphyrin 14 through an anhydride link. A 
spacer (Fmoc-AEEA-OH) was inserted between BN[7-14] and the lysine in order to 
increase both the solubility in water and the distance between the peptide and the 
porphyrin. All the reactions were performed on solid phase following the general 
procedure already described, unless otherwise specified. 
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Scheme 18: Synthetic strategy using Fmoc-Lys(Mtt)-OH 
 
 
3.4.2. SYNTHESIS OF THE BN[7-14]-PORPHYRIN 
 
The first two coupling reactions in SP involved the spacer (Fmoc-AEEA-OH), and the 
Fmoc-Lys(Mtt)-OH. These compounds are commercially available and have been 
previously used in solid phase synthesis [149]. The coupling reactions showed in 
Scheme 19 were successfully completed. More in detail, the NHFmoc of the 
glutammine of BN[7-14] sequence was deprotected and reacted with the carboxylic 
group of the PEG chain. When the coupling reaction was complete, the NHFmoc of the 
PEG chain was deprotected and coupled with the carboxylic group of the Fmoc-
Lys(Mtt)-OH to give BNPL-Fmoc-Mtt.  
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Scheme 19: Synthetic rote for BNPL-Fmoc-Mtt. Reagents and conditions: a) piperidine, DMF, 2'+10'; b) TBTU, 
DIPEA,2,6 lutidine, DMF, 1h, rt  
In order to check the purity of these intermediate, a small amount of BNPL-Fmoc-Mtt 
was cleaved and an RP-UPLC-MS analysis was performed. Since the Mtt group was 
released during the cleavage reaction, BNPL-Fmoc and the oxidized BNPL-Fmoc OX 
were observed in the RP-UPLC-MS chromatogram (Figure 58).  
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Figure 58: RP-UPLC-MS (ACN/H2O) of BNPL-Fmoc, 276 nm  
The Mtt protecting group was released from BNPL-Fmoc-Mtt in order to couple the ε-
amino group with the carboxylic group of the functionalized TACN 4. This deprotection 
leaves untouched the other acid-labile protecting groups of the peptide sequence such 
as Trt and Boc. The choice of the acid for this purpose depends on the type of resin 
used in SP. Usually TFA in CH2Cl2 containing TIPS (to prevent the reattachment of the 
trityl cations) or with TES in HFIP and TFE are used on hydrophilic resin and the 
mixture AcOH and TFE in CH2Cl2 is used on hydrophobic resin [150]. The Mtt 
deprotection had to be quantitative, but only a small amount of acid was used to avoid 
the cleavage of the peptide from the resin. Furthermore this deprotection could not be 
monitored either by Kaiser test and RP-UPLC-MS. In fact the Mtt groups were released 
during the RP-UPLC-MS analysis. A solution made of 92:5:3 CH2Cl2/TIPS/TFA was 
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used to wash the resin containing BNPL-Fmoc-Mtt several times before the Mtt 
removal and then the resin was left shaking twice for 10 minutes with a 94:5:1 
CH2Cl2/TIPS/TFA solution. The resin changed color both during the washes and the 
deprotection steps [150-152]. Another test was performed to evaluate the presence of 
still protected amino groups: a small sample of resin was collect and 1-2 drops of TFA 
were added and the non-immediate orange TFA color indicated that all the Mtt groups 
were correctly removed [102]. Before proceeding with the coupling reaction with 4, a 
model reaction with a simple amino acid (Fmoc-Gly-OH) was performed in order to 
evaluate if both the Mtt deprotection and the following coupling were quantitative 
(Scheme 20). After the deprotection of the α-Fmoc amino group of the glycine, the RP-
UPLC-MS analysis showed BNPLG and the correspondent BNPLGOX without any trace 
of the starting material. 
  
Scheme 20: Synthetic rote for BNPLG. Reagents and conditions: a) 92:5:3 CH2Cl2/TIPS/TFA 10'x2; b) TBTU, DIPEA, 
2,6 lutidine, DMF, 1h, rt c) piperidine, DMF, 2'+10' 
After the Mtt deprotection, the coupling between the BNPLFmoc and chelator 4 was 
carried out in a quantitative yield (Scheme 21). The reaction lasted overnight and 4 
equivalents of 4 were required. The α-Fmoc amino group was deprotected in a basic 
environment affording the pure BNPLT. 
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 Scheme 21: Synthetic rote for BNPLFmoc, BNPLT and BNPLTA. Reagents and conditions: a) 92:5:3   
CH2Cl2/TIPS/TFA 10'x2, b) TBTU, DIPEA, 2,6-lutidine, DMF, overnight, rt c) piperidine, DMF, 2'+10' 
At this stage the oxidation of the methionine was investigated. Indeed the main side 
reaction is the acid catalyzed oxidation of methionine that can occur during the 
cleavage and deprotection reactions. It is to note that scavengers such as DTE, EDT, 
2-mercaptoethanol or ethyl methyl sulfide should be added to the cleavage solution in 
order to prevent this oxidation [153].  In order to reduce the oxidation, in the following 
steps TIPS was replaced with 2-mercaptoethanol in the cleavage solution. From the 
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RP-UPLC-MS of BNPLT the peak of BNPLTOX is less intense than the peak of BNPLTA 
(Figure 59).  
 
 
 
Figure 59: RP-UPLC-MS (ACN/H2O) of BNPLT 
Then the α-amino group of the lysine of BNPLT was reacted with a large excess of 
succinic anhydride (Scheme 21). The resin was left shaking overnight in order to obtain 
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BNPLTA in a quantitative yield. Before performing the coupling reaction with the 
porphyrin 14, the carboxylic group of BNPLTA was coupled to the amine of the 
benzylamine as model reaction in order to evaluate its reactivity. The product was 
obtained with a good grade of purity after 1.5 hours of reaction using 4 equivalents of 
benzylamine in the presence of TBTU, DIPEA, 2,6-lutidine in DMF. Following a similar 
procedure, the coupling reaction between porphyrin 14 and BNPLTA was performed: 
the carboxylic group of the resin was activated both with TBTU and HOBt in base 
solution, and 3 equivalents of the porphyrin 14 were used (Table 4 and Scheme 22) 
[154]. 
 
Scheme 22: Synthetic rote for BNPLTAP. Reagents and conditions: TBTU, HOBt, DIPEA, 2,6 lutidine, DMF, overnight, 
N2, rt  
The RP-UPLC-MS analysis of the crude solid obtained after the cleavage reaction 
showed a superposition of BNPLTA and a side product (sp) with m/z 1509.9. Also the 
mass value of the correspondent spOX was observed (m/z 1524.9). The product 
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BNPLTAP could only be observed from MALDI-Tof spectrum where a mixture of 
BNPLTAPOX (with the methionine oxidized to sulfoxide) and BNPLTAP2 OX (with the 
methionine oxidized to sulfur) were observed (Figure 60).  
Figure 60: MALDI-Tof of the crude BNPLTAP 
In order to increase the reaction yield, the coupling reaction between BNPLTA and 
porphyrin 14 was performed in different conditions (Table 4) but a mixture of BNPLTA, 
sp and BNPLTAP was always obtained. 
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Trial 
number 
Type of 
synthesis 
Reactives Conditions 
Porphyrin’s 
equivalents 
 
1 
 
SPPS 
 
TBTU, DIPEA, 2,6 Lutidine 
 
 
DMF, 24 h, rt 
 
2 
 
2 
 
SPPS 
 
TBTU, DIPEA, 2,6 Lutidine, HOBt 
 
 
DMF, 24 h, rt 
 
3 
 
3 
 
SPPS 
 
TBTU, DIPEA, HOBt, 2,6 Lutidine, 
Rodamine(4.9 equiv)  
 
DMF, 24 h, rt 
 
3 
 
4 
 
SPPS 
 
TBTU, DIPEA, HOBt, 2,6 Lutidine, PPh3 
 
 
DMF, 24 h, rt 
 
3 
 
5 
 
SPPS 
 
TBTU, DIPEA, HOBt, 2,6 Lutidine [155] 
 
 
MW (60°C,10') 
 
3 
 
6 
 
solution 
 
TBTU, HOBt, DIPEA, 2,6 Lutidine 
 
DMF, 24 h, rt 
 
0.5 
  
Table 4: trials for the synthesis of BNPLTAP. The fluorine dye (rhodamine) was left shaking with the resin for 1 h before 
performing the coupling reaction with porphyrin 14 in order to prevent the stacking of the porphyrin to the resin. The 
rhodamine should stack into the resin and all the equivalents of the porphyrin should be free to react with the carboxylic 
group. The coupling reaction was also performed in a microwave reactor but degradation of the product was observed 
from RP-UPLC-MS. 
 
Since the yield of the coupling reaction could not be improved, an analytical method 
was studied in order to purify the product. In the analytical HPLC (linear gradient from 0 
to 100% of CH3CN over 30 minutes) a peak was observed at 420 nm (blu arrow, Figure 
61 A). This peak splits into two peaks at 275 nm (red arrows, Figure 61 B). The peak 
indicated with the blue arrow was collected and its MALDI-Tof spectrum showed the 
simultaneous presence of BNPLTA, BNPLTAP and sp. 
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Figure 61: Analytical HPLC chromatogram of the crude BNPLTAP, zoom at 400 nm (A) and at 275 nm (B),  zorbax 
column. 
A successful separation of the crude BNPLTAP was obtained using a slower gradient 
(from 0 to 50% of CH3CN over 55 minutes). In this way BNPLTAP, BNPLTA and sp 
could be separated (Figure 62). Indeed, the peak at retention time 31.7 min 
corresponds to BNPLTA. Since the peak at the retention time 38.0 min absorbs both at 
275 nm and 400 nm, it was attributed to BNPLTAP. The peak at the retention time 32.7 
min was collected and analyzed by RP-UPLC-MS, and the sp (m/z 1509.9) was 
observed. The peaks at retention time 27.0 and 36.5 min might correspond respectively 
to BNPLTAOX and BNPLTAPOX.   
B A 
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Figure 62: analytical HPLC chromatogram of BNPLTA (1) and BNPLTAP (2), 275 nm 
After a scale up of the reaction, the crude product was purified by preparative HPLC 
adapting this analytical method. The pail purple fraction was isolated and the MALDI-
Tof spectrum showed the pure BNPLTAP in different oxidation states (Figure 63). 
Unfortunately, only 0.3 mg of the purified product were obtained. BNPLTAP was 
soluble in water soluble, as well as all the intermediates of this synthetic route.  
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Figure 63: MALDI-Tof spectrum of the pure BNPLTAP  
Due to the low quantity of BNPLTAP isolated, the reaction of coordination with Re(I) 
could not be performed. Since only the last coupling reaction gave a complex mixture 
of products (Figure 63, compare the analytical HPLC of BNPLTA and BNPLTAP) we 
decided to choose a functionalized fullerene for the reaction with BNPLTA. 
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3.4.3. SYNTHESIS OF A BN[7-14]-FULLERENE 
This work was performed in collaboration with professor Tatiana Da Ros 
Fullerene C60 is a carbon nanomaterial with a soccer-ball shape that is biocompatible 
and non-toxic. Fullerene presents interesting applications such as in, antibacterial, anti-
HIV, radiopharmaceuticals and drug delivery fields. This carbon material can also act 
as a photosensitizer in PDT since it generates singlet oxygen after irradiation, and 
some fullerene derivative are in vivo preclinical stage for this treatment [155]. Fullerene 
absorbs in the visible region thanks to its extended π-conjugated system, and after 
irradiation (532 nm) produces reactive oxygen species (ROS). Unfortunately C60 
present also several limitations as: i) it is very hydrophobic and its application in the 
biomedical field are limited; ii) it aggregates in polar solvents; iii) it absorbs in the blue-
green visible light at wavelengths not ideal for PDT. However a lot of research is 
ongoing to overcome these problems and allow a possible use in the biomedical field, 
especially in PDT [156-160]. 
Therefore a coupling reaction between BNPLTA and a functionalized fullerene was 
performed on solid phase (Scheme 23). To assure that fullerene was completely 
solubilized during the reaction, high volumes of a base solution made of DIPEA and 
2,6-lutidine in 1:1 dioxane/NMP were used (1 mg/3 mL) and the solution of the 
fullerene was added in  portion (5 x 6 mL) over 72 hours. Then the resin was left 
shaking for additional 72 hours at room temperature shielded from light.  
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Scheme 23: Synthetic rote for BNPLTAF. Reagents and conditions: TBTU, DIPEA, 2,6-lutidine in DMF, 1:1 
dioxane/NMP, 6 days, rt 
After the cleavage reaction (TFA, H2O, TIPS) 8.27 mg of a water soluble brown solid 
were obtained. As for BNPLTAP also the RP-UPLC-MS of BNPLTAF showed the 
presence of BNPLTA and some side products with retention times close to the one of 
BNPLTA. In the MALDI-Tof spectrum the molecular peak of BNPLTAF plus water was 
observed (Figure 64). The HPLC purification of the crude BNPLTAF did not afford the 
pure product, for this reason no further reaction could be performed. 
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Figure 64: MALDI-Tof of BNPLTAF 
 
3.5. CONCLUSIONS 
 
The peptide BN[7-14] was successfully connected to the porphyrin 14 together with a 
functionalized chelator TACN 4 using either click chemistry or a coupling reaction 
approach. The peptide BN[7-14] was also connected to a functionalized fullerene 
together with a functionalized chelator TACN 4. Unfortunately in both cases the 
products were obtained in a very small amount, and the coordination reaction with 
rhenium for both the porphyrin-peptide and the fullerene-peptide was not feasible.  
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3.6. EXPERIMENTAL PART 
 
Mono and bidimensional (HSQC) NMR spectra were recorded on a 500 MHz Bruker 
spectrometer. All the spectra were run at ambient temperature and chemical shifts 
were referenced to the peak of residual non deuterated solvent (δ = 3.31 for CD3OD). 
The UV-Vis spectra were performed at ambient temperature on a Varian Cary 100 
spectrophotometer. The RP-UPLC-MS were performed using a Bruker Daltonics HCT 
6000 mass spectrometer. RP-UPLC-MS were recorded with a Waters Acquity™ 
system equipped with a PDA detector and auto-sampler using an Acquity UPLC BEH 
C18 column (21.50 x 1.7 mm). RP-UPLC-MS were performed by using a Bruker 
Daltonics HCT 6000 mass spectrometer. RP-UPLC-MS was performed at a flow rate of 
0.6 mL min-1 with a linear gradient of A (double-distilled water containing 0.1% v/v 
formic acid) and B (acetonitrile): t =0 min, 0, 5% B; t = 0.25 min, 5% B; t = 4.5 min, 
100% B; t = 5.0 min, 100% B. The matrix-assisted laser desorption/ionization time of 
fight mass spectrometry (MALDI-Tof) mass spectra were measured on a Bruker 
Daltonics Autofex. The experiments were performed in reflector (RP) or linear (LP) 
mode with positive polarity using acyano-4-hydroxy-cinnamic acid on a Prespotted 
AnchorChip (PAC HCCA) or sinapinic acid (SA) as the matrix. Microwave reactions 
were perfomed using a  Biotage  Initiator+  Robot  Eight instrument. Preparative HPLC 
purification was carried out with a Varian ProStar system and an Agilent Zorbax 300 
SB-C18 prep column (5 μm particle size, 300 Å pore size, 15021.2 mm, flow rate: 20 
mL min-1) using a method which depends on the type of compound to be purified. 
Semipreparative HPLC was carried out Merck Hitachi system (interface D-7000, diode 
array detector L-7455, pump L-7100) and an Agilent Zorbax 300 SB-C18 colunm (5 um 
particle size, 300 A pore size, 250x9.4 mm). Analytical HPLC was performed with a 
VWR Hitachi Chromaster system with a 5110 pump, 5210 auto-sampler, 5310 column 
oven and 5430 diode array detector with a Macherey-Nagel nucleosil 100-5 C18 
column (5 μm particle size, 100 Å pore size, 250 x 3 mm, flow rate: 0.75 mL min-1) or 
with an Agilent Zorbax 300 SB-C18 analytical column (3.5 µm particle size, 300 Å pore 
size, 150 x 4.6 mm, flow rate: 0.75 mL min-1). The analytical runs were performed with 
a method which depended on the type of compound to be purified. The TLC was 
performed using silica gel/UV TLC, 0.25 mm, aluminum support. Chemicals and 
solvents were of reagent grade or better and purchased from commercial suppliers and 
were used without further purification unless otherwise specified. The peptide synthesis 
was performed according to a procedure reported by Metzler-Note [161]. The peptides 
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were prepared manually in one-way polypropylene syringes (5, 10 or 100 mL) 
equipped with a frit using a standard solid-phase peptide synthesis procedure. All the 
reactions were carried out using a mechanical shaker. The synthetic steps related to 
the porphyrin were characterized with mono, bidimensional spactra and RP-UPLC-MS. 
Each step of the SPPS was characterized by RP-UPLC-MS.  
 
Porphyrin 23 
 
To a solution of Boc-L-2-propargylglycine (5.03 mg, 0.0237 mmol, 1.4 equiv) in 
anhydrous DMF (0.5 mL) HOBt (5.38 mg, 0.0398 mmol, 2.4 equiv) and EDCI (7.30 mg, 
0.0382 mmol, 2.3 equiv) were added and the resulting solution was stirred for 30 min. 
To this solution a purple solution of the porphyrin 13 (19.5 mg, 0.0166 mmol) and 
DMAP (5.45 mg, 0.0446 mmol, 2.7 equiv) in anhydrous DMF (2.5 mL) was added. The 
resulting solution was stirred shielded from light for 20 h at rt. The reaction was 
monitored by TLC (CH3CN/KNO3sat/H2O 4:0.3:1, Rf = 0.55). The charged porphyrin 
was purified by repeated precipitation (CH3OH/Et2O) and extensive washed with Et2O 
and CH2Cl2 to remove the excess of the reagents and of the Boc-L-2-propargylglycine. 
Yield: 69% (15.7 mg). 
1H NMR (CD3,OD): δ=9.38 (d, 6H, 2,6py, J=6.1 Hz), 9.38-8.96 (br s, 8H, βH), 8.96 (d, 
6H, 3,5py, J=5.9 Hz), 8.32 (m, 4H, oPh+mPh), 4.80 (s, 9H, CH3py), 4.22 (m, 1H, CH 
2’), 3.84 (t, 2H, CH2O, J=5.2 Hz), 3.79 (m, 4H, CH2O+CH2NH), 3.73 (m, 2H, CH2O), 
3.63 (t, 2H, CH2O, J=5.6 Hz), 3.45 (m, 2H, CH2NH), 2.62 (ddd, 1H, CH2 3’, J=2.6, 6.0, 
16.8 Hz), 2.58 (ddd, 1H, CH2 3’, J=2.7, 7.4, 16.9 Hz), 10.0, 6.7, 2.7), 2.32 (s, 1H, CH2 
5’), 1.32 ppm (s, 9H, CH3Boc) 
ESI-MS m/z: 515.5 [M]2+, 344.1 [M]3+, 310.8 [M-Boc]
3+. 
RP-UPLC-MS (sample dissolved in CH3OH) tr: 0.9 min 
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Porphyrin 24 
 
To a solution of porphyrin 23 (15.70 mg, 0.0114 mmol) in CH2Cl2 (2 mL) TFA (2 mL) 
was added. The solution was stirred at rt for 4 h shielded from light, then the solvent 
was removed under reduced pressure until the complete elimination of the excess of 
TFA, to give the product as TFA salt. The reaction was quantitative and the product 
was used in the following step without further purification. 
TLC: CH3CN/KNO3sat/H2O 4:0.3:1, Rf = 0.35. 
  
Porphyrin 25 
 
To a solution of 4 (6.87 mg, 0.0177 mmol, 1.5 equiv) in anhydrous DMF (1 mL) HOBt 
(4.30 mg, 0.0318 mmol, 2.8 equiv) and EDCI (6.09 mg, 0.0318 mmol, 2.8 equiv) were 
added and the resulting solution was stirred for 45 min. To this solution a purple 
solution of the porphyrin 24 (0.0114 mmol) and DMAP (3.32 mg, 0.0272 mmol, 2.4 
equiv) in DMF (1.5 mL) was added. The reaction was left under stirring at rt for 21 h. 
The reaction was monitored by TLC (CH3CN/KNO3sat/H2O 4:0.3:1, Rf = 0.55). The 
charged porphyrin was purified by repeated precipitation (CH3OH/Et2O) and extensive 
washes with Et2O and CH2Cl2 to remove the excess both of the reagents and of the 
ligand. 
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Yield: 69.52% (13 mg). 
1H NMR (CD3,OD): δ=9.39 (d, 6H, 2,6py, J=5.1 Hz), 8.97 (m, 6H, 3,5py, J=5.5 Hz), 
9.39-8.97 (br s, 8H, βH), 8.30 (m, 4H, oPh+mPh), 4.80 (s, 9H, CH3py), 4.51 (t, 1H, CH 
2’), 3.82 (m, 2H, CH2O), 3.77 (m, 4H, CH2O+CH2NH), 3.72 (m, 2H, CH2O), 3.62 (m, 
2H, CH2O), 3.52-3.34 (m, CH2NH+CH2 c/b, 6H), 3.25 (m, CH2 c/b, 4H), 3.14 (m, CH2 
c/b, CH2 d, 4H) 2.67 (m, 6H, CH2 a + CH2 3'), 2.36 (m/s, 1H, CH 5'), 1.39-1.36-1.30 
ppm (3s, 18H, CH3Boc). 
ESI-MS m/z: 650.1 [M]2+, 433.8 [M]3+, 367.1 [M-2Boc]
3+, 275.6 [M-2Boc+H]
4+ 
RP-UPLC-MS (sample dissolved in CH3OH) tr: 1 min 
 
Porphyrin 26 
 
Porphyrin 25 (3 mg) and zinc acetate dihydrate (2.5 mg, 0.0114 mmol, 6 equiv) were 
dissolved in methanol (3 mL) obtaining a deep green-brown solution. The reaction was 
left under stirring at rt for 2 h and was monitored by TLC (CH3CN/KNO3sat/H2O 4:0.3:1, 
Rf = 0.32) and UV-Vis. Then the solvent was removed under reduce pressure. The 
reaction is quantitative and the product was used in the following step without further 
purification to remove the excess of zinc acetate.  
ESI MS m/z: 681 [M]2+, 454.6 [M]3+, 291.2 [M-2Boc+ H]
4+ 
RP-UPLC-MS tr: 1.85 min. 
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Porphyrin 26 
 
To porphyrin 25 (0.00061 mmol), 35 µL (0,00122 mmol, 2 equiv) of a solution 0.035 
mM of sodium ascorbate in 1:2 H2O/tBuOH, 43 µL (0.00037 mmol, 0.6 equiv) of a 
solution 0.0086 mM of copper sulfate in the 1:2 mixture H2O/tBuOH and 16 µL (0.0016 
mmol, 2.6 equiv) of a solution 0.1 mM of the azido acid pentanoic in the mixture 1:2 
H2O/tBuOH were added. 200 µL of a mixture made of 1:2 H2O/tBuOH were added to 
this solution. The solution was left under stirring at rt and the reaction was monitored by 
TLC (CH3CN/KNO3 sat/H2O 4:0.3:1, Rf = 0.27) and RP-UPLC. After 22 h less than 50% 
of the product was obtained. Then the reaction yield was increased in a microwave 
reactor at 85 °C for 17 min. The reaction was complete after adding 2, 0.83 and 6.5 
equivalents of sodium ascorbate, copper sulfate and azido acid pentanoic respectively 
in 1:2 H2O/tBuOH and heating for further 10 min at 85 °C.  
ESI MS m/z: 753.5 [M]2+, 502.6 [M]3+, 327.2 [M-2Boc+H]
4+ 
RP-UPLC-MS tr: 1.9 min.  
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Porphyrin 28 
 
 
 
 
 
 
 
 
 
To 5.05 mg of porphyrin 26 (0.00196 mmol), copper sulphate (1.33 mg, 0.0084 mmol, 
4.3 equiv), sodium ascorbate (3.47 mg, 0.0175 mmol, 8.9 equiv) were dissolved in 6 
mL of 1:2 mixture H2O/tBuOH and the solution was heated in a microwave reactor at 
85 °C for 1 h obtaining a precipitate and a green solution. The reaction was checked by 
RP-UPLC-MS and then the solvent was evaporated. The product was obtained in a 
mixture with the oxidized product.  
ESI MS m/z: 1097.7 [BNN3 2 OX+H]
+, 1081.7 [BNN3 OX+H]
+, 815.2 [MOX]
3+, 810.7 [M]3+, 
612.0 [MOX+H]
 4+, 607.8 [M+H] 4+, 549.5 [BNN3 OX+2H]
2+, 541.4 [BNN3 2 OX+2H]
2+, 489.9 
[MOX+2H]
 5+, 486.5 [M+2H] 5+. 
RP-UPLC-MS tr: 1.90 min (MOX+ BNN3 ox) 1.80 min (M + BNN3 2 ox). 
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Porphyrin 29 
 
 
 
 
 
 
 
 
Porphyrin 28 was dissolved in TFA (1.5 mL) and the solution was stirred for 2 h 
shielded from light, then the solvent was removed under reduced of pressure and the 
product was suspended in CH3OH. 100 µL of TEA were added to precipitate product 
precipitated and s washed several times with Et2O. The product was purified by 3 
semipreparative HPLC.  
Semipreparative HPLC, flow rate = 4mL/min, linear gradient of A (double distilled H2O 
containing 0.1% v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 0 min, 10% B; t 
= 3 min, 10% B; t = 45 min, 50% B; t = 47 min, t =95% B; t= 49 min, t= 95%, tr: 17.5 min 
ESI MS m/z: 1148.6 [M 2 OX+K]
2+, 766.8 [M 2 OX+K]
3+, 575.4 [M 2 OX+K]
 4+, 460.5 [M 2 
OX+K+H]
 5+. 
RP-UPLC-MS tr: 1.5 min. 
 
General procedure for the synthesis of peptides on solid phase 
Polystyrene resin beds of TentaGel S RAM (capacity 0.24 mmol g-1 or 0.26 mmol g-1) 
were inserted into a polypropylene syringe equipped with a frit swollen in DMF for at 
least 1 h before use. The resin was deprotected with piperidine (20% v/v in DMF) first 
for 2 min and then for 10 min. Either after 2 and 10 min the resin was washed with DMF 
(5 mL × 5), CH2Cl2 (5 mL × 5) and DMF (5 mL × 5). A first Fmoc-protected amino acid 
(4.5 equiv) was first pre-activated using TBTU (4 equiv) and base solution (3.8%v/v 
DIPEA, 3.8% v/v 2,6 lutidine in DMF, usually 3 mL for 1 g of resin) for 5 min and then 
reacted with the resin for 1h. Afterwards, the resin beads were washed with DMF (5 mL 
× 5) and CH2Cl2 (5 mL ×5), and a Kaiser test was performed to check if the coupling 
was complete. Then the resin beads were washed with DMF (5 mL × 5). The amino 
group of the first amino acid was deprotected with piperidine (20% v/v in DMF) for 2 
Targeting prostate cancer cells 
 
122 
 
min and then for 10 min. Either after 2 and 10 min the resin was washed with DMF (5 
mL × 5), CH2Cl2 (5 mL × 5) and DMF (5 mL × 5). The second Fmoc-protected amino 
acid was added following the same procedure for the first one. When the whole peptide 
sequence was synthesized, the peptide was cleaved from the resin, checked and 
eventually purified.  
 
General procedure for the cleavage of the product from the resin 
After the Fmoc deprotection of the last amino acid the resin was shrunk in CH3OH and 
dried under vacuum for at least 30 min. A small amount of the product was cleaved 
using 4 mL of a mixture 38:1:1 v/v/v TFA:H2O:TIPS for 4 h at rt. The resin was filtrate 
and the filtrate was evaporated under vacuum. The peptide was precipitated and 
washed with cold Et2O and dried under vacuum. The purity of the compound was 
check by RP-UPLC-MS and analytical HPLC and then eventually purified by 
preparative HPLC. For BNPLT, BNPLTA and BNPLTAP TIPS was replaced with 2-
mercapthoetanol.  
 
 
BN[7-14] 
  
 
The peptide was synthetized on solid phase following the general procedures 
described for the synthesis of peptides on solid phase. 
ESI MS m/z: 940.6 [M+H]+, 470.8 [M+2H]2+, 956.6 [MOX+H]
+, 478.8 [MOX+2H]
+2, 978.5 
[MOX+Na]
+ 
RP-UPLC-MS tr: 1.45 min (MOX), 1.65 min (M). 
Analytical HPLC, Zorbax column, linear gradient of A (double distilled H2O containing 
0.1% v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 0 min, 5% B; t = 3 min, 
5% B; t = 20 min, 80% B; t = 22 min, 100% B; t = 23 min, 100 % B; tr: 10.2 min (MOX), 
10.7 min (M). 
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BNN3  
  
52 mg of BN[7-14] (0.01352 mmol) were used to couple the azidopentanoic acid (8.71 
mg, 0.06084 mmol, 4.5 equiv) using TBTU (17.7 mg, 0.05512, 4 equiv) and base 
solution (2 mL) following the general procedure described for the SPPS. After the 
cleavage the product was purified by preparative HPLC. 
ESI MS m/z: 1065.8 [M+H]+, 533.5 [M+2H]2+, 1081.8 [MOX+H]
+, 541.6 [MOX+2H]
+2. 
RP-UPLC-MS tr: 1.90 min (MOX), 2.15 min (M). 
Preparative HPLC, linear gradient of A (double distilled H2O containing 0.1% v/v TFA) 
and B (ACN, Sigma-Aldrich HPLC-grade), t = 0 min, 5% B; t = 23 min, 100% B; t = 30 
min, 100% B; t = 32 min, 5% B; tr: 16 min. 
 
BNPL-Fmoc-Mtt  
 
129.6 mg of peptide BN7-14 (0.0312 mmol) were used to couple first Fmoc-AEEA-OH  
(54.11 mg, 0.1404 mmol, 4.5 equiv) and then Fmoc-Lys (Mtt) (87.72 mg, 0.1404 mmol, 
4.5 equiv)  using TBTU (40.1 mg, 0.1249 mmol, 4 equiv for the first coupling, 54.11 mg, 
0.1404 mmol, 4.5 equiv  for the second coupling) and 3.5 mL of base solution for each 
coupling reaction, following the general procedure described for the synthesis of 
peptides on solid phase. Both coupling reactions last over an hour.  
ESI MS m/z: 1436.8 [M(-Mtt)+H]
+, 718.6 [M(-Mtt)+2H]
2+, 1451.8 [M(-Mtt)OX+H]
+, 726.5 [M(-
Mtt)OX+2H]
+2. 
RP-UPLC-MS tr: 1.95 min (MOX) 2.05 min (M). 
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BNPL  
 
 
 
 
 
ESI MS m/z: 1213.8 [M+H]+, 607.5 [M+2H]2+, 1229.7 [MOX+H]
+, 615.5 [MOX+2H]
2+, 
410.7 [MOX+3H]
3+, 
RP-UPLC-MS tr: 1.35 min (MOX) 1.5 min (M). 
 
BNPL-Fmoc  
 
 
 
 
To remove the Mtt protecting group the resin with the peptide BNPL-Fmoc-Mtt (10 mg, 
0.0024 mmol) was washed several times with a solution 92:3:5 CH2Cl2/TFA/TIPS or 
with a solution 94:5:1 CH2Cl2/TIPS/TFA. Then the resin was left shaking for 10 min with 
1 mL of the fresh solution 92:3:5 CH2Cl2/TIPS/TFA  for two times or for 30 min with 2 
mL of the fresh solution 94:5:1 CH2Cl2/TIPS/TFA. During the washes the solution 
becomes deep yellow and then transparent. The resin was then washed with DMF (5 
mL x 5) and CH2Cl2 (5 mL x 5) and a Kaiser test was performed. The resin was finally 
washed with DMF (5 mL x 5). As from RP-UPLC-MS the starting material could not be 
detected, this intermediate was used for the following coupling reaction without further 
characterization. 
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BNPLG 
 
 
 
 
 
10 mg of peptide BNPLFmocMtt (0.0024 mmol) were used to couple Fmoc-glycine 
(3.21 mg, 0.0108 mmol, 4.5 equiv) using TBTU (3.08 mg, 0.0096 mmol, 4 equiv) and 
1mL of base solution, following the general procedure described for the synthesis of 
peptides on solid phase. The RP-UPLC-MS analysis was performed after the Fmoc 
deprotection. 
ESI MS m/z: 1270.8 [M+H]+, 636.0 [M+2H]2+, 1286.8 [MOX+H]
+, 644.0 [MOX+2H]
 2+. 
RP-UPLC-MS tr: 1.25 min (MOX), 1.4 min (M). 
 
 
BNPLT 
 
 
 
 
129.6 mg of peptide BNPL-Fmoc-Mtt (0.0312 mmol) were used to couple the chelator 
(44 mg, 0.1135 mmol, 3.6 equiv) using TBTU (40.1 mg, 0.1217 mmol, 4 equiv.) and 2 
mL of base solution, following the general procedure described for the synthesis of 
peptides on solid phase. The resin was left shaking overnight. The RP-UPLC-MS 
analysis was performed after the Fmoc deprotection. 
ESI MS m/z: 1382.9 [M+H]+, 692.1 [M+2H]2+, 461.8 [M+3H]3+, 1398.9 [MOX+H]
+, 700.0 
[MOX+2H]
+2, 467.1 [MOX+3H]
3+. 
RP-UPLC-MS tr: 1.25 min (MOX), 1.35 min (M). 
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BNPLTA 
 
The resin with the peptide BNPLFT (129.6 mg, 0.0312 mmol of BN[7-14]) was reacted 
with the anhydride (14.04 mg, 0.1404 mmol, 4.5 equivalents) dissolved in base solution 
(2 mL) overnight.  
ESI MS m/z: 1483.9 [M+2H]+, 742.1 [M+2H]2+, 1498.9 [MOX+H]
+, 750.1 [MOX+2H]
+2. 
RP-UPLC-MS tr: 1.3 min (MOX), 1.45 min (M). 
Analytical HPLC, Zorbax column, linear gradient of A (double distilled water containing 
0.1% v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 0 min, 5% B; t = 3 min, 
5% B; t = 20 min, 80% B; t = 22 min, 100% B; t = 23 min, 100 % B; tr: 11.25 min (MOX) 
12.2 min (M). 
Analytical HPLC, nucleosil column, linear gradient of A (double distilled water 
containing 0.1% v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 0, 2% B; t = 2, 
2% B; t = 55, 50% B; t = 58, 50% B; t = 58.1, 100% B; tr: 28.0 min (MOX) 31.7 min (M). 
 
 
BNPLTAB  
 
The resin with the peptide BNPLFTA (5 mg, 0.0012 mmol) was first pre-activated using 
TBTU (1.54 mg, 0.0048 mmol, 4 equiv) in base solution (300 µL) for 10 min. Then a 
solution of benzylamine (590 µL, 0.5787 mmol, 4.5 equiv) in base solution (300 µL) 
was added and then the resin was left shaking for over an hour.  
ESI MS m/z: 1571.9 [M]+, 786.7 [M+2H]2+, 525 [M+3H]3+, 1588.0 [MOX]
+. 
RP-UPLC-MS tr: 1.45 min (MOX), 1.6 min (M). 
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BNPLTAP  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18.3 mg of resin with the peptide BNPLFTA (0.0044 mmol) were first pre-activated 
using TBTU (7.4 mg, 0.0230 mmol, 5.2 equiv) and HOBt (3.2 mg, 0.0237 mmol, 5.4 
equiv) in anhydrous base solution (1.5 mL) for 15 min. Then a solution of porphyrin 
(15.6 mg, 0.0133 mmol, 3 equiv) in anhydrous base solution (1.5 mL) was added and 
the resin was left shaking for 20 h under a nitrogen atmosphere. Afterwards, the resin 
beads were washed with DMF (5 mL × 5), CH2Cl2 and DMF (5 mL × 5). The product 
was cleaved from the resin using a cleavage solution made of 38:1:1 v/v/v TFA:H2O:2-
mercaptoethanol obtaining 21.3 and 47.11 mg of crude product respectively from the 
first and second cleavage. The product was dissolved in 20 mL of distilled H2O 
containing 0.1% v/v TFA and two preparative HPLC were performed. The product was 
checked by RP-UPLC-MS, analytical HPLC and MALDI. Overall 0.30 mg of pure 
product were obtained.  
RP-UPLC-MS tr: 1.5 min. 
Preparative HPLC, method A, linear gradient of A (double distilled H2O containing 0.1% 
v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 5 min, 5% B; t = 130 min, 34% 
B; t = 135 min, 34% B; t = 145 min, 50% B; t = 150 min, 90 % B; t = 155 min, 5% B; tr: 
87 min. 
Preparative HPLC, method B, linear gradient of A (double distilled H2O containing 0.1% 
v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 5 min, 5% B; t = 130 min, 26% 
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B; t = 140 min, 35% B; t = 145 min, 50% B; t = 150 min, 100 % B; t = 160 min, 100% B; 
t = 165 min, 5% B; tr: 110 min. 
Analytical HPLC, Zorbax column, flow rate = 0.75 mL/min, inject volume= 100µL, linear 
gradient of A (double distilled H2O containing 0.1% v/v TFA) and B (ACN, Sigma-
Aldrich HPLC-grade), t = 0 min, 5% B; t = 3 min, 5% B; t = 20 min, 80% B; t = 22 min, 
100% B; t = 23 min, 100 % B; tr:12.3 
Analytical HPLC, nucleosil column, linear gradient of A (double distilled water 
containing 0.1% v/v TFA) and B (ACN, Sigma-Aldrich HPLC-grade), t = 0, 2% B; t = 2, 
2% B; t = 55, 50% B; t = 58, 50% B; t = 58.1, 100% B; tr: 36.1 min (MOX) 37.9 min (M). 
tr: 11.7 min (MOX) 12.2 min (M). 
MALDI-Tof m/z: 2301.2 [M+H]+, 2317.2  [MOX+H]
+, 2333.2 [M2 OX+H]
+. 
 
BNPLTAF 
 
 
 
 
 
 
 
 
 
 
 
70.14 mg ( 0.017 mmol) of resin with the peptide BNPLFTA was divided in three 100 
mL syringes, the functionalized fullerene (65.35 mg, 0.0648 mmol, 3.81 equiv) was 
divided in 15 equal portions and each portion was dissolved in 10 mL of a base 
solution made of DIPEA, 2,6-lutidine in dioxane and NMP 1:1. 5 portions were added in 
3 days for each syringe. Before each addition of the fullerene, the resin was pre-
activated using 4.5 equiv TBTU (128.51 mg, 0.4002 mmol, 23.54 equiv) in DMF (10 mL 
total) for 15 min. The resin was then left shaking for other 3 days at rt. The solution was 
then filtered and the resin was then washed several times with DMF, CH2Cl2, CH3OH, 
dioxane and NMP. After the cleavage of the product from the resin the product was 
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characterized with RP-UPLC-MS and MALDI. 8.27 mg of impure product were 
obtained. 
RP-UPLC-MS tr: 1.55 min. 
MALDI-Tof m/z: 2375.8 [M+H2O]. 
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